

# CURRICULUM VITAE

**Gary L. Clayman, D.M.D., M.D., F.A.C.S.**

## PRESENT TITLE AND AFFILIATION

### Current Appointment

Director of the Clayman Thyroid Cancer Center, Tampa General Hospital, Tampa, FL

### Previous Appointment

Professor of Surgery, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1991-August 31, 2016 2016

Medical Director, Health Care Provider Experience, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Deputy Head Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Chief Section, Head and Neck Endocrine Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

Distinguished Chair of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 2003- August 31, 2016

### Dual/Joint/Adjunct Appointment

Professor and Biologist, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

## CITIZENSHIP

United States

## OFFICE ADDRESS

Clayman Thyroid Cancer Center

Tampa General Hospital

2352 Creel Lane

Wesley Chapel, FL 33544

Phone: (813) 940-3130

Fax: (813) 972-0077

Website [thyroidcancercenter.com](http://thyroidcancercenter.com)

Email [Clayman@thyroidcancercenter.com](mailto:Clayman@thyroidcancercenter.com)

## EDUCATION

### Degree-Granting Education

Case Western Reserve University, Cleveland, OH, BS, 1978, Biology

Case Western Reserve University School of Dentistry, Cleveland, OH, DDS, 1982, Dental

Northeastern Ohio Universities College of Medicine, Rootstown, OH, MD, 1986, Medical

University of Minnesota, Minneapolis, MN, MS, 1991, Immunobiology

Case Western Reserve University, Cleveland, OH, DMD, 2006, Dental Medicine

### Postgraduate Training

Subintern in Oral and Maxillofacial, Case Western Reserve University Hospital, Cleveland, OH, Dr. Goldberg, 1/1981-1/1982

Intern in General Surgery, Hennepin County Medical Center, Minneapolis, MN, Dr. Hitchcock, 1/1986-1/1987

Research Fellow, Advisor Elizabeth Grimm, Ph.D., The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1989-1/1990

Resident in Otolaryngology/Oncology Head and Neck Surgery, University of Minnesota, Minneapolis, MN, Chairman, George Adams, M.D., 1/1989-1/1991

Fellow in Head and Neck Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Chairman, Helmuth Goepfert, M.D., 1/1991-1/1993

## **CREDENTIALS**

### **Board Certification**

Otolaryngology/Head & Neck Surgery, 1991 (written), 1991

Otolaryngology/Head and Neck Surgery (oral), 1992

Joint Council for Approval of Advanced Training in Head & Neck Oncologic Surgery, 1992

American Board of Otolaryngology, 1992

Fellow of the American College of Surgeons, 1995

### **Licensures**

#### **Active**

TX, H-5856, 1989

CA, G127858, 2013

FL, ME 125739, 10/2015-1/2018

#### **Inactive**

OH, 17114, 1986

MN, 312594, 1991

## **EXPERIENCE/SERVICE**

### **Academic Appointments**

Dentist, Self Employed Private Practice, Cleveland, OH, 1982-1986

Clinical Fellow, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1991-1992

Adjunct Assistant Professor, The University of Texas-Houston Dental Branch, Houston, TX, 1993-1996

Assistant Professor, of Surgery (tenure track) Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1993-1996

Associate Faculty, UT Houston Health Science Center, The Graduate School of Biomedical Sciences, Houston, TX, 1993-present

Adjunct Associate Professor, Houston Dental Branch, The University of Texas, Houston, TX, 1996-2000

Associate Professor and Associate Surgeon (tenure), Department of Head and Neck Surgery, The University of Texas-Houston Dept. of Head and Neck Surgery, Houston, TX, 1/1996-1/2000

Associate Professor, Department of Otorhinolaryngology and Communicative Sciences, Baylor College of Medicine, Houston, TX, 1/1996-1/2004

Associate Professor and Biologist (tenure), Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1998-1/2000

Professor and Biologist, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2000-present

Adjunct Professor, Department of Oral Biology and Oral Medicine, The University of Texas-Houston Dental Branch, Houston, TX, 1/2000-present

Alando J. Ballantyne Distinguished Chair of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003-present

Deputy Head Division of Surgery,, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2003-August 31, 2016

Professor of Surgery, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2005-August 31, 2016

Adjunct Professor, Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine Voluntary Faculty, Houston, TX, 7/2007-August 31, 2016

**Administrative Appointments/Responsibilities**

Director of Research, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1994-2005

Program Director for Multidisciplinary Program in Head and Neck Cancer Research, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1996-August 31, 2016

Deputy Chairman, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1997-1/2004

Chief Section, Head and Neck Endocrine Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005-August 31, 2016

Associate Medical Director, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2006-August 31, 2016

Medical Director, Health Care Provider Experience, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2013-August 31, 2016

**Other Appointments/Responsibilities**

Member, American Head & Neck Society, Houston, TX, 1995-present

Member, Publication Committee, Society of Head and Neck Surgeons, N/A, 1/1996-1/1998

Member, Resident Award Committee, Society of Head and Neck Surgeons, N/A, 1/1996-1/1998

Member, Research Committee, Society of Head and Neck Surgeons, N/A, 1/1996-1/1998

Chairman, Head and Neck Oncology Committee, American Association of Otolaryngology and Head and Neck Surgery, Houston, TX, 1/1996-1/2002

Member, SPF Advisory Committee, The American Cancer Society, N/A, 1/1996-present

Member, Endocrine Surgery Committee, American Academy of Otolaryngology, N/A, 1/1996-present

Chairman, Head and Neck Oncology Committee, American Academy of Otolaryngology and Head and Neck, N/A, 1/1997-2000

Member, Research and Grants Committee, American Academy of Otolaryngology, N/A, 1/1997-1/2003

Member, Oral Cancer Advisory Committee, National Institute of Dental and Craniofacial Research, N/A, 1/1997-present

Member, Review Committee, Nature Medicine, N/A, 1/1997-present

Member, Research Committee, American Head and Neck Society, N/A, 1/1998-present

Member, Ad hoc Neck Dissection Classification Committee, American Head and Neck Society, N/A, 1/1999-1/2004

Member, Advanced Training Council for Head and Neck Surgical Oncology, American Head and Neck Society, N/A, 1/1999-1/2004

Member, W.M. Keck Center Steering Committee for Gene Therapy, N/A, 1/1999-present

Chairman, Council of Specialty Societies, Harris County Medical Society, N/A, 1/2000-1/2001

Member, Executive Board, Harris County Medical Society, N/A, 1/2000-2004

Member, Pittsburgh Eye and Ear Foundation Scientific Advisory Committee, N/A, 1/2002-present

Member, Council for Advanced Training (ATC), American Head and Neck Society, \_\_, 1/2003-2004

Member, External Advisory Board, Vanderbilt SPORE, Head and Neck Cancer, \_\_, 1/2003-present  
Executive Council of, American Head and Neck Society, N/A, 1/2004-2008

Member, Council for Advanced Training (ATC), American Head and Neck Society, N/A, 1/2004-1/2009

Member, Head and Neck Cancer (THANC) Foundation Scientific Committee, N/A, 1/2004-present

Member, Current Cancer Therapy Reviews Editorial Board, Bentham Science Publishers, Ltd., \_\_, 2005

Member, American Thyroid Association (ATA), N/A, 2005

Member, American Head and Neck Society Executive Council, \_\_, 1/2005-1/2010

Member, Advanced Training Council, N/A, 1/2005-1/2010

Member, NCI SPORE Standing Special Emphasis Panel (SEP), N/A, 1/2005-present

External Advisory Committee, Head & Neck Specialized Program of Research Excellence (SPORE), The University of Pennsylvania Health System, N/A, 2006-present

Member Editorial Board, Head & Neck, Houston, TX, 2007-present

Chairman, Endocrine Committee, American Head and Neck Society, Houston, TX, 2007-present

#### **Endowed Positions**

Alando J. Ballantyne Distinguished Chair of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2003-August 31, 2016

#### **Consultantships**

N/A

#### **Military or Other Governmental Service**

N/A

#### **Institutional Committee Activities**

RTOG Head and Neck Oncology Research Committee, UT MD Anderson Cancer Center, Member, 1/1995-1995

Institutional Research Board/Surveillance Committee, UT MD Anderson Cancer Center, Member, 1/1995-1/1997

Graduate Medical Education Committee, UT MD Anderson Cancer Center, Member, 1/1995-1/1997

Subcommittee of Head and Neck Surgery, RTOG, UT MD Anderson Cancer Center, Member, 1/1995-2000

Research Program Development and Direction Committee, UT MD Anderson Cancer Center, Member, 1/1995-present

Clinical Affairs Committee, UT MD Anderson Cancer Center, Member, 1/1996-1997

Promotions Committee-Division of Surgery, UT MD Anderson Cancer Center, Member, 1/1996-1/1997

PRS Research Committee, UT MD Anderson Cancer Center, Member, 1/1996-present

Faculty Senate Research Issues Committee, UT MD Anderson Cancer Center, Member, 1/1996-present

Current Drugs Committee, UT MD Anderson Cancer Center, Member, 1/1997-present

Faculty Senate Promotions and Tenure Committee, UT MD Anderson Cancer Center, Member, 1/2000-2004

SPORE Executive Committee, UT MD Anderson Cancer Center, Member, 1/2002-present

Mohs Surgery Steering Committee, UT MD Anderson Cancer Center, Member, 1/2002-present

Division of Surgery Executive Committee, UT MD Anderson Cancer Center, Member, 1/2002-present

Research Laboratory Space Subcommittee of the Research Council, Member, 1/2005-1/2008

Faculty Achievement Awards Committee, Member, 2008-present

Division of Surgery Mentorship Program, Chair, 2008-present

Division of Surgery Educational Initiatives Committee, Chair, 11/2011-present

IPRPET Leadership, UT MD Anderson Cancer Center, Chair, 2014-present

Making Cancer History Patient Care Award Nomination Committee, Chairman, 1/2015-present

### **HONORS AND AWARDS**

Jaycee Wives Scholarship, 1976

Pre-professional Scholarship Program, Case Western Reserve University, 1976

Miller, Ratner, Safran Foundation Scholarship, 1977

Summa Cum Laude, Case Western Reserve University, 1980

Alpha Omega Dental Honor Society, 1981

Phi Beta Kappa Honor Society, 1981

Undergraduate Research Award, Case Western Reserve University School of Dentistry, 1982

Charles F. Block Foundation Scholarship Award, 1983

Alpha Omega Alpha Honor Society, 1984

Arthur W. Shagrin Scholarship of Northeastern, Ohio Universities College of Medicine, 1984

Joseph A. Keller Award, 1985

Medical Student Fellowship Award, American College of Surgeons, 1985

Outstanding Surgical Intern of the Year, Hennepin County Medical Center, 1987

Resident/Fellow Clinical Award, Society of Head and Neck Surgeons, 1990

Residents Research Award, The American College of Surgeons, 1990

Janssen Case History Contest, Allergy and Immunology, 1991

Texas Division Oncology Fellowship Award, The American Cancer Society, 1991

University Cancer Foundation Award, The University of Texas MD Anderson Cancer Center, 1991

Scholastic Award in Basic Science Research, American Society for Head/Neck Surgery, 1992

Career Development Award, American Cancer Society, 1993

Faculty Scholar Award, The University of Texas MD Anderson Cancer Center, 1998

Stubenbord Award for Research, Cornell University, 1998

American Academy of Otolaryngology-Head and Neck Surgery Honor Award, 2000

Americas Top Doctors, Castle Connolly Medical Ltd., 2001-present

NEOUCOM Distinguished Alumni, Northeastern Ohio University College of Medicine, 2002

Alando J. Ballantyne Distinguished Chair in Head and Neck Surgery, 2003-present

Best Doctors in America, 2003-present

Percy Memorial Research Award, 2004

Alpha Omega Alpha Honor Society, 2005

Exceptional Leadership & Support as a Mentor, The University of Texas MD Anderson Cancer Center, 2005

Texas Super Doctors, 2005-present

2007 Best Boss Award, The University of Texas MD Anderson Cancer Center, 2007

Patient's Choice Award, 2008-present

2009 Herbert Birkett Memorial Lecture Award, Medico Chirurgical Society, Montreal, Canada, 2009

U.S. News and World Report Top Doctors 2011- present

Castle Connolly Medical LTD, Americas Top Doctors., 2001-present

Director's Service Award, National Cancer Institute, 2013-present

2014 Cattlemen for Cancer Research (CCR) Hero Award., Cattlemen of Cancer Research, 2014-present

Newsweek Health: Top Cancer Doctors 2015, Castle Connolly Medical LTD, 2015-present

2016 Top 100 Health Professional, International Biographical Centre (IBS), 2016-present

## **RESEARCH**

### **Grants and Contracts**

#### **Funded**

Co-Investigator, 0.6 months, Cancer Center Support Core Grant - Project 9, P30CA16672, NIH/NCI, PI - John Mendelsohn, MD, 7/1/1978-6/30/2012 (\$68,416/year)

Co-Principal Investigator, 1%, Training of Academic Head and Neck Surgical Oncologist, T32 CA 60374, Institutional National Research Science Award, PI - Jeffrey Myers, MD, 8/1/1995-6/30/2011 (\$125,570/year)

Project Leader, 0.6 months, M.D. Anderson Cancer Center SPORE in Head and Neck Cancer - DRP, P50CA97007, NIH/NCI, PI - Scott Lippman, MD, 9/22/2002-7/31/2013 (\$303,406/year)

Co-Investigator, 0.12 months, Molecular Epidemiology of Head and Neck Cancer, R01ES11740, NIH/NIEHS, PI - WEI, 3/1/2008-2/28/2013, \$396,189

#### **Pending**

N/A

#### **Other**

N/A

#### **Completed**

Co-Investigator, Cancer Center Support Core Grant – Central Media Laboratory, NIH 5P30 CA16672, NIH/NCI, PI - John Mendelsohn, 7/1/1978-6/30/2003 (\$70,178/year)

Co-Investigator, Cancer Center Support Core Grant (Project 12), NIH 5P30 CA16672, NIH/NCI, PI - John Mendelsohn, 7/1/1978-6/30/2003 (\$5,305/year)

Principal Investigator, Training of Academic Head and Neck Surgical Oncologist, T32 CA60374, Institutional National Research Science Award, 8/1/1995-5/31/2005 (\$100,080/year)

Co-Investigator, Biology & Chemoprevention of Head & Neck Cancer Project 3: Translational Study of Retinoid Reversal of Oral Carcinogenesis, 2P01 CA 52051, NIH-NCI, PI - Waun Ki Hong, 2/1/1996-11/30/2001 (\$164,934/year)

Investigator, Biology of Non-Melanoma Skin Cancer Growth and Progression, POI CA68233, NIH, 5/6/1996-7/31/2001 (\$88,398/year)

Co-Investigator, Randomized Adjuvant Therapy of Head and Neck Cancer, RO1 CA75603, NIH, PI - Ki Shin, 9/1/1998-8/31/2002 (\$104,780/year)

Co-Investigator, Molecular Epidemiology of Head and Neck Cancer, RO1 ES11740-0, NIH, PI - Qingyi Wei, 9/30/2001-8/31/2006 (\$2,225,133/year)

Principal Investigator, Biology of Headpin (a novel serpin) in Oral Cancer, DE13954, NIH, 1/15/2002-12/31/2006 (\$225,000/year)

Co-Investigator, M.D. Anderson Cancer Center SPORE in Head and Neck Cancer, NIH-NCI, P50CA97007, NIH/NCI, PI - Waun Ki Hong, 7/1/2002-6/30/2007 (\$1,750,000/year)

#### **Not Funded**

Principal Investigator, Collection of Normal Human Blood, LAB99-404, n/a, 1/15/2002-12/31/2006, \$1,125,000 (\$225,000/year)

Principal Investigator, Molecular Characterization and Therapy of Non-melanoma Skin Cancer, CA095104, NIH, 4/1/2003 (\$1,422,400/year)

#### **Protocols**

##### **Funded**

Principal Investigator, Phase III Trial to Preserve the Larynx: induction chemotherapy and radiation therapy vs. concomitant chemotherapy and radiation therapy vs. radiation therapy, RTOG 91-11, 1992-2000

Principal Investigator, Establishment of a Tumor Registry for Non-Melanoma Skin Cancers, LAB92-039, 1992-2009, \$500,000, NIH Skin Grant

Principal Investigator, Establishment of a DNA Library for Head and Neck Cancers, LAB92-018, 1992-present, \$1,125,000 (\$225,000/year), NIH Headpin Grant

Co-Principal Investigator, Adjuvant therapy for aggressive squamous carcinoma of the skin, ID94-013, PI - Scott Lippman, MD, 1994-2005, MDACC/ NCI

Principal Investigator, Collection of Normal Human Blood, LAB99-404, 1999-present, \$225,000 (\$1,125,000/year)

Principal Investigator, Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity, Oral Pharynx via Adenoviral Vector INGN 201 (Ad5CMV-p53), ID00-193, 2000-2007, \$667,377, NIH SPORE Grant

Principal Investigator, A Phase III, Multi-Center, Open-Label, Randomized Study to Compare the Overall Survival and Safety of Bi-weekly Intratumoral Administration of INGN 201 vs Weekly Methotrexate in Patients with Refractory Squamous Cell Carcinoma of Head and Neck, ID00-006, 2000-2009, \$687,657, Introgen

Principal Investigator, A Phase III, Multi-Center, Open-Label, Randomized Study to Compare the Effectiveness and Safety of Intratumoral Administration of INGN 201 in Combination with Chemotherapy vs Chemotherapy Alone in 288 Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck, ID00-342, 2001-2009, \$515,328, Introgen

Co-Principal Investigator, A trial of lymphatic mapping and sentinel node lymphadenectomy for patients with T1 or T2 clinically N0 oral cavity squamous cell carcinoma, ACOSOG Z0360, PI - Jeffrey Myers, MD, 2002-2008, ACOSOG

Principal Investigator, Establishment of a Prospective Library of Non-Mucosal Head and Neck Tissues, LAB02-039, 2002-present, \$1,125,000 (\$225,000/year), NIH Headpin Grant

Co-Principal Investigator, Pahes II trial of surgery with perioperative INGN 201 (AD5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx and larynx., SWOG S0011, PI - Ehab Hanna, MD, 2005-2007, SWOG

##### **Unfunded**

Principal Investigator, Impact of radiotherapy on parathyroid autotransplantation in patients undergoing thyroidectomy, RCR 02-071, 2002-2008

Principal Investigator, Ultrasound for long term assessment of the lateral neck compartments in thyroid cancer, RCR 02-072, 2002-2009

Principal Investigator, Clinical protocol for wildtype P53 gene induction in premalignancies of squamous epithelium of the oral cavity and oral pharynx via an adenoviral vector, INGN 201 (Ad5CMV-p53), ID00-193S, 2003-2010

Principal Investigator, Processing of human explant normal, non-malignant tissue, LAB 03-0746, 2003-present

Principal Investigator, Gene Discovery Pathways, LAB 04-0397, 2004-present

Principal Investigator, Immunohistochemical, methylation and LOH studies of novel gene discoveries, LAB 04-0205, 2004-present

Principal Investigator, Markers for Papillary Thyroid Carcinoma Recurrences, LAB 06-0312, 2006-present

Principal Investigator, Ultrasound for long term assessment of the lateral neck compartments in thyroid cancer, DR08-0682, 2008-present

Collaborator, A Registry and Tissue Acquisition Protocol for the Treatment of Squamous Cell Carcinoma of the Head and Neck (SCCHN), LAB 08-0848, PI - Jeffrey Myers, M.D., 2009-present

Principal Investigator, Long term outcomes after central compartment lymph node dissection for recurrent well differentiated thyroid cancer, DR08-0872, 2009-present

Co-Principal Investigator, Patterns of loco-regional recurrences of squamous cell and basal cell carcinomas following resection by Mohs Surgery., DR 09-0294, PI - Deborah MacFarlane, MD, 2009-present

## **Patents and Technology Licenses**

### **Patents**

The University of Texas MD Anderson Cancer Center, Methods and Compositions for the Diagnosis and Treatment of Cancer, International U.S. 96/19083 NO 60/007,810 9INGN022, 11/27/1996, Issued

The University of Texas MD Anderson Cancer Center, Augmentation of Cell Growth Inhibition by Enhancement of Intercellular Communication, U.S. 09/442,911, 10/21/1998, Issued

Oncolab, Worlds First Human General Cancer Antiobody, U.S. 5/866,690, 2/2/1999, Issued

The University of Texas MD Anderson Cancer Center, Methods and Compositions of a Novel Serine Protease Inhibitor, U.S. 60/151,776, 0, 8/31/2000, Issued

The University of Texas MD Anderson Cancer Center, Isolation of a Cell-Specific Internalizing Peptide that Infiltrates Tumor Tissue for Targeted Drug Delivery, U.S. 09/899,376, 2/2/2001, Issued

### **Technology Licenses**

N/A

## **Grant Reviewer/Service on Study Sections**

Oral Cancer Advisory Board, The National Institute of Dental and Craniofacial Research, Reviewer, 2000-present

Integrative and Clinical Endocrinology Study Section, The University of Texas MD Anderson Cancer Center, Reviewer, 2010-present

## **PUBLICATIONS**

### **Peer-Reviewed Original Research Articles**



1. **Clayman GL**, Goldberg JS. The incidence of forceps delivery among patients with TMJ problems. A preliminary study. *J Craniomandibular Pract* 2(1):46-50, 1983 Dec-1984 Feb, 1983. PMID: 6590651.
2. Papadimitrakopoulou, Oh Y, El-Naggar A, Izzo J, **Clayman GL**, Mao L. Presence of multiple contiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. *Clin Cancer Res* 4(3):539-544, 1988.
3. **Clayman GL**, Marentette LJ. Complex odontoma of the maxillary sinus with a complete dentition. *Otolaryngol Head Neck Surg* 101(5):581-3, 11/1989. PMID: 2512540.
4. **Clayman GL**, Adams GL. Permanent tracheostomy with cervical lipectomy. *Laryngoscope* 100(4):422-4, 4/1990. PMID: 2319895.
5. **Clayman GL**, Savage HE, Ainslie N, Liu FJ, Schantz SP. Serologic determinants of survival in patients with squamous cell carcinoma of the head and neck. *Am J Surg* 160(4):434-8, 10/1990. PMID: 2221250.
6. Schantz, **Clayman GL**, Liu FJ, Lavedan P, Taylor DL, Pellegrino C, Savage HE. The in-vivo biologic effect of interleukin-2 and interferon-alpha on natural immunity in patients with head and neck cancer. *Arch Otolaryngol* 116(11):1302-1308, 1990.
7. **Clayman GL**, Adams GL, Paugh DR, Koopmann CF. Intracranial complications of paranasal sinusitis: a combined institutional review. *Laryngoscope* 101(3):234-9, 3/1991. PMID: 2000009.
8. **Clayman GL**, Adams GL. Modifications of the mandibular swing for preservation of occlusion and function. *Head Neck* 13(2):102-6, Mar-Apr, 3/1991. PMID: 2022473.
9. **Clayman GL**, Liu FJ, Taylor DL, Savage HE, Lavedan P, Buchsbaum RM, Trujillo JM, Schantz SP. Immunomodulation of the induction phase of lymphokine-activated killer activity by acute phase proteins. *Otolaryngol Head Neck Surg* 105(1):26-34, 7/1991. PMID: 1715542.
10. Schantz, **Clayman GL**, Dimery I, Moric R. Combination interleukin-2 and interferon-alpha in head and neck cancer. *Cancer Bulletin* 43:133-138, 1991.
11. **Clayman GL**, Liu FJ, Savage HE, Taylor DL, Lavedan P, Buchsbaum RM, Pellegrino C, Trujillo JM, Young G, Schantz SP. Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa. *Arch Otolaryngol Head Neck Surg* 118(1):41-8, 1/1992. PMID: 1370199.
12. Byers RM, **Clayman GL**, Guillamondequi OM, Peters LJ, Goepfert H. Resection of advanced cervical metastasis prior to definitive radiotherapy for primary squamous carcinomas of the upper aerodigestive tract. *Head Neck* 14(2):133-8, Mar-Apr, 3/1992. PMID: 1601650.
13. **Clayman GL**, Adams GL, Szachowicz EH, Dehner LP, Gorlin RJ. Oropharyngeal desmoid fibromatosis, congenital glaucoma and cataracts, and a calvarial defect: a new syndrome. *Otolaryngol Head Neck Surg* 107(1):109-14, 7/1992. PMID: 1528590.
14. Schantz SP, Dimery I, Lippman SM, **Clayman GL**, Pellegrino C, Morice R. A phase II study of interleukin-2 and interferon-alpha in head and neck cancer. *Invest New Drugs* 10(3):217-23, 8/1992. PMID: 1428731.
15. **Clayman GL**, Young G, Taylor DL, Savage HE, Lavedan P, Schantz SP. Detection of regulatory factors of lymphokine-activated killer cell activity in head and neck cancer patients treated with interleukin-2 and interferon alpha. *Ann Otol Rhinol Laryngol* 101(11):909-15, 11/1992. PMID: 1444098.
16. **Clayman GL**, Young G, Grimm E, Taylor DL, Schantz SP. Immunologic profile of a patient with dyskeratosis congenital. *Immunol Allergy Prac* 14(4):17-24, 1992.
17. Lydiatt DD, Savage HE, **Clayman GL**, Liu FJ, Sample D, Schantz SP. Serologic determinants of survival in patients with head and neck cancer: validating a clinical prediction model. *Laryngoscope* 103(1 Pt 1):13-6, 1/1993. PMID: 8421413.
18. **Clayman GL**, Taylor DL, Liu FJ, Lavedan P, Savage HE, Schantz SP. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells. *Laryngoscope* 103(3):299-307, 3/1993. PMID: 7680086.
19. **Clayman GL**, Raad II, Hankins PD, Weber RS. Bacteriologic profile of surgical infection after antibiotic prophylaxis. *Head Neck* 15(6):526-31, Nov-Dec, 11/1993. PMID: 8253560.
20. **Clayman GL**, Cohen JI, Adams GL. Neoplastic seeding of squamous cell carcinoma of the oropharynx. *Head Neck* 15(3):245-248, 1993.

21. Stern, Goepfert H, **Clayman GL**, Byers R, Wolf P. Orbital preservation in maxillectomy. *Otolaryngol Head Neck Surg* 109(1):111-115, 1993.
22. **Clayman GL**, Wang SW, Nicolson GL, El-Naggar A, Mazar A, Henkins J, Blasi F, Goepfert H, Boyd DD. Regulation of urokinase-type plasminogen activator expression in squamous-cell carcinoma of the oral cavity. *Int J Cancer* 54(1):73-80, 1993.
23. Juarez, **Clayman GL**, Nakajima M, Tanabe KK, Saya H, Nicolson GL, Boyd D. Role and regulation of expression of 92-kDa type-IV collagenase (MMP-9) in 2 invasive squamous-cell-carcinoma cell lines of the oral cavity. *Int J Cancer* 55(1):10-18, 1993.
24. Stern, Goepfert H, **Clayman GL**, Byers R, Ang KK, EL-Naggar AK, Wolf P. Squamous cell carcinoma of the maxillary sinus. *Arch Otolaryngol Head Neck Surg* 119(9):964-969, 1993.
25. Duvic M, Nelson DC, Annarella M, Cho M, Esgleyes-Ribot T, Remenyik E, Ulmer R, Rapini RP, Sacks PG, **Clayman GL**. Keratinocyte transglutaminase expression varies in squamous cell carcinomas. *J Invest Dermatol* 102(4):462-9, 4/1994. PMID: 7908683.
26. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, **Clayman GL**. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. *Cancer Res* 54(14):3662-7, 7/1994. PMID: 8033080.
27. **Clayman GL**, Stewart MG, Weber RS, el-Naggar AK, Grimm EA. Human papillomavirus in laryngeal and hypopharyngeal carcinomas. Relationship to survival. *Arch Otolaryngol Head Neck Surg* 120(7):743-8, 7/1994. PMID: 8018327.
28. **Clayman GL**, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. *Cancer Res* 55(1):1-6, 1/1995. PMID: 7805018.
29. Clayman GL, Weber RS, Guillaumondegui O, Byers RM, Wolf PF, Frankenthaler RA, Morrison WH, Garden AS, Hong WK, Goepfert H. Laryngeal preservation for advanced laryngeal and hypopharyngeal cancers. *Arch Otolaryngol Head Neck Surg* 121(2):219-23, 2/1995. PMID: 7840931.
30. Janot F, el-Naggar AK, Morrison RS, Liu TJ, Taylor DL, Clayman GL. Expression of basic fibroblast growth factor in squamous cell carcinoma of the head and neck is associated with degree of histologic differentiation. *Int J Cancer* 64(2):117-23, 4/1995. PMID: 7615354.
31. **Clayman GL**, Trapnell BC, Mittereder N, Liu TJ, Eicher S, Zhang S, Shillitoe EJ. Transduction of normal and malignant oral epithelium by an adenovirus vector: the effect of dose and treatment time on transduction efficiency and tissue penetration. *Cancer Gene Ther* 2(2):105-11, 6/1995. PMID: 7621258.
32. Liu TJ, el-Naggar AK, McDonnell TJ, Steck KD, Wang M, Taylor DL, Clayman GL. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. *Cancer Res* 55(14):3117-22, 7/1995. PMID: 7606733.
33. Kanjilal S, Strom SS, **Clayman GL**, Weber RS, el-Naggar AK, Kapur V, Cummings KK, Hill LA, Spitz MR, Kripke ML, et al. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. *Cancer Res* 55(16):3604-9, 8/1995. PMID: 7627969.
34. **Clayman GL**. Gene therapy for head and neck cancer. *Head Neck* 17(6):535-41, 11/1995. PMID: 8847213.
35. Trizna Z, **Clayman GL**, Spitz MR, Briggs KL, Goepfert H. Glutathione s-transferase genotypes as risk factors for head and neck cancer. *Am J Surg* 170(5):499-501, 11/1995. PMID: 7485742.
36. Beckhardt RN, Kiyokawa N, Xi L, Liu TJ, Hung MC, el-Naggar AK, Zhang HZ, **Clayman GL**. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 121(11):1265-70, 11/1995. PMID: 7576473.
37. **Clayman GL**, DeMonte F, Jaffe DM, Schusterman MA, Weber RS, Miller MJ, Goepfert H. Outcome and complications of extended cranial-base resection requiring microvascular free-tissue transfer. *Arch Otolaryngol Head Neck Surg* 121(11):1253-7, 11/1995. PMID: 7576471.
38. Lengyel, Gum R, Juarez J, **Clayman GL**, Seiki M, Sato H, Boyd D. Induction of Mr 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. *Cancer Res* 55(4):963-967, 1995.

39. **Clayman GL**, Chamberlain RM, Lee JJ, Lippman SM, Hong WK. Screening at a health fair to identify subjects for an oral leukoplakia chemoprevention trial. *J Cancer Educ* 10(2):88-90, 1995. PMID: 7669540.
40. Fueyo J, Gomez-Manzano C, Yung WK, **Clayman GL**, Liu TJ, Bruner J, Levin VA, Kyritsis AP. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. *Oncogene* 12(1):103-10, 1/1996. PMID: 8552379.
41. El-Naggar AK, Lovell M, Killary AM, **Clayman GL**, Batsakis JG. A mucoepidermoid carcinoma of minor salivary gland with t (11; 19) (q21; p13.1) as the only karyotypic abnormality. *Cancer Genet Cytogenet* 87(1):29-33, 3/1996. PMID: 8646736.
42. **Clayman GL**, Liu TJ, Overholt SM, Mobley SR, Wang M, Janot F, Goepfert H. Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). *Arch Otolaryngol Head Neck Surg* 122(5):489-93, 5/1996. PMID: 8615965.
43. El-Naggar AK, Hurr K, Huff V, **Clayman GL**, Luna MA, Batsakis JG. Microsatellite instability in preinvasive and invasive head and neck squamous carcinoma. *Am J Pathol* 148(6):2067-72, 6/1996? PMID: 8669490.
44. Garden AS, Morrison WH, **Clayman GL**, Ang KK, Peters LJ. Early squamous cell carcinoma of the hypopharynx: outcomes of treatment with radiation alone to the primary disease. *Head Neck* 18(4):317-22, 7/1996. PMID: 8780942.
45. Gillenwater A, Xu XC, el-Naggar AK, **Clayman GL**, Lotan R. Expression of galectins in head and neck squamous cell carcinoma. *Head Neck* 18(5):422-32, 9/1996. PMID: 8864733.
46. Eicher SA, **Clayman GL**, Liu TJ, Shillitoe EJ, Storthz KA, Roth JA, Lotan R. Evaluation of topical gene therapy for head and neck squamous cell carcinoma in an organotypic model. *Clin Cancer Res* 2(10):1659-64, 10/1996. PMID: 9816113.
47. Kim, Fan Y, Papadimitrakopoulou V, **Clayman GL**, Hittelman WN, Hong WK, Lotan R, Mao L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. *Cancer Res* 56(11):2519-2521, 1996.
48. Califano, van der Riet P, Westra W, Nawroz H, **Clayman GL**, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic progression model for head and neck cancer: implications for field cancerization. *Cancer Res* 56(11):2488-2492, 1996.
49. Mobley, **Clayman GL**. The promise of gene therapy in head and neck cancer. *Curr Opin Otolaryngol Head Neck Surg* 4:82-87, 1996.
50. Overholt SM, Liu TJ, Taylor DL, Wang M, El-Naggar AK, Shillitoe E, Adler-Storthz K, John LS, Zhang WW, Roth JA, **Clayman GL**. Head and neck squamous cell growth suppression using adenovirus-p53-FLAG: a potential marker for gene therapy trials. *Clin Cancer Res* 3(2):185-91, 2/1997. PMID: 9815671.
51. Geara FB, Glisson BS, Sanguineti G, Tucker SL, Garden AS, Ang KK, Lippman SM, **Clayman GL**, Goepfert H, Peters LJ, Hong WK. Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma: results of a matched cohort study. *Cancer* 79(7):1279-86, 4/1997. PMID: 9083147.
52. **Clayman GL**, Ebihara S, Terada M, Mukai K, Goepfert H. Report of the Tenth International Symposium of the Foundation for Promotion of Cancer Research: Basic and Clinical Research in Head and Neck cancer. *Jpn J Clin Oncol* 27(5):361-8, 10/1997. PMID: 9390219.
53. Hunt, Deng J, Liu TJ, Wilson-Heiner M, Swisher SG, **Clayman GL**, Hung MC. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian carcinoma cell lines and does not require p53. *Cancer Res* 57(21):4722-4726, 1997.
54. Papadimitrakopoulou, Izzo J, Lippman SM, Lee JS, Fan YH, **Clayman GL**, Ro JY, Hittelman WN, Lotan R, Hong WK, Mao L. Frequent inactivation of p16ink4a in oral premalignant lesions. *Oncogene* 14(15):1799-1803, 1997.
55. El-Naggar, Lai S, **Clayman GL**, Lee JK, Luna MA, Goepfert H, Batsakis JG. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. *Am J Pathol* 151(6):1767-1774, 1997.

56. Xia W, Lau YK, Zhang HZ, Liu AR, Li L, Kiyokawa N, **Clayman GL**, Katz RL, Hung MC. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. *Clin Cancer Res* 3(1):3-9, 1997. PMID: 9815530.
57. Henderson YC, Liu TJ, **Clayman GL**. A simple and sensitive method for detecting adenovirus in serum and urine. *J Virol Methods* 71(1):51-6, 3/1998. PMID: 9628221.
58. **Clayman GL**, Frank DK. Selective neck dissection of anatomically appropriate levels is as efficacious as modified radical neck dissection for elective treatment of the clinically negative neck in patients with squamous cell carcinoma of the upper respiratory and digestive tracts. *Arch Otolaryngol Head Neck Surg* 124(3):348-52, 3/1998. PMID: 9525524.
59. Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, Lawhorn K, Gillenwater AM, Ang KK, **Clayman GL**, Callender DL, Hong WK, Lippman SM. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. *J Clin Oncol* 16(4):1325-30, 4/1998. PMID: 9552033.
60. **Clayman GL**, Eicher SA, Sicard MW, Razmpa E, Goepfert H. Surgical outcomes in head and neck cancer patients 80 years of age and older. *Head Neck* 20(3):216-23, 5/1998. PMID: 9570627.
61. **Clayman GL**, el-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. *J Clin Oncol* 16(6):2221-32, 6/1998. PMID: 9626224.
62. Jin YT, Kayser S, Kemp BL, Ordonez NG, Tucker SL, **Clayman GL**, Goepfert H, Luna MA, Batsakis JG, El-Naggar AK. The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma. *Cancer* 82(11):2159-65, 6/1998. PMID: 9610695.
63. Ke LD, Adler-Storthz K, **Clayman GL**, Yung AW, Chen Z. Differential expression of epidermal growth factor receptor in human head and neck cancers. *Head Neck* 20(4):320-7, 7/1998. PMID: 9588705.
64. Woods KV, Adler-Storthz K, **Clayman GL**, Francis GM, Grimm EA. Interleukin-1 regulates interleukin-6 secretion in human oral squamous cell carcinoma in vitro: possible influence of p53 but not human papillomavirus E6/E7. *Cancer Res* 58(14):3142-9, 7/1998. PMID: 9679982.
65. Woods KV, El-Naggar A, **Clayman GL**, Grimm EA. Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. *Cancer Res* 58(14):3132-41, 7/1998. PMID: 9679981.
66. Frank DK, Liu TJ, Frederick MJ, **Clayman GL**. Combination E2F-1 and p53 gene transfer does not enhance growth inhibition in human squamous cell carcinoma of the head and neck. *Clin Cancer Res* 4(9):2265-72, 9/1998. PMID: 9748148.
67. Frank DK, Frederick MJ, Liu TJ, **Clayman GL**. Bystander effect in the adenovirus-mediated wild-type p53 gene therapy model of human squamous cell carcinoma of the head and neck. *Clin Cancer Res* 4(10):2521-8, 10/1998. PMID: 9796986.
68. Henderson YC, Wang E, **Clayman GL**. Genotypic analysis of tumor suppressor genes PTEN/MMAC1 and p53 in head and neck squamous cell carcinomas. *Laryngoscope* 108(10):1553-6, 10/1998. PMID: 9778300.
69. Mobley SR, Liu TJ, Hudson JM, **Clayman GL**. In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck: a research model for combination gene therapy. *Arch Otolaryngol Head Neck Surg* 124(1):88-92, 1998. PMID: 9440786.
70. Gillenwater, Jacob R, Ganeshappa R, Kepm B, El-Naggar AK, Palmer JL, **Clayman GL**, Mitchell MF, Richards-Kortum R. Noninvasive diagnosis of oral neoplasia based on fluorescence spectroscopy and native tissue autofluorescence. *Arch Otolaryngol Head Neck Surg* 124:1251-1258, 1998.
71. Mao, El-Naggar AK, Papadimitrakopoulou V, Shin DM, Shin HC, Fan Y, Zhou X, **Clayman GL**, Lee JJ, Lee JS, Hittelman WN, Lippman SM, Hong WK. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. *J Natl Cancer Inst* 90(20):1545-1551, 1998.

72. Sturgis EM, **Clayman GL**, Guan Y, Guo Z, Wei Q. DNA repair in lymphoblastoid cell lines from patients with head and neck cancer. *Arch Otolaryngol Head Neck Surg* 125(2):185-90, 2/1999. PMID: 10037285.
73. Frederick MJ, Holton PR, Hudson M, Wang M, **Clayman GL**. Expression of apoptosis-related genes in human head and neck squamous cell carcinomas undergoing p53-mediated programmed cell death. *Clin Cancer Res* 5(2):361-9, 2/1999. PMID: 10037186.
74. Liu TJ, Wang M, Breau RL, Henderson Y, El-Naggar AK, Steck KD, Sicard MW, **Clayman GL**. Apoptosis induction by E2F-1 via adenoviral-mediated gene transfer results in growth suppression of head and neck squamous cell carcinoma cell lines. *Cancer Gene Ther* 6(2):163-71, 3/1999. PMID: 10195883.
75. **Clayman GL**, Frank DK, Brusio PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. *Clin Cancer Res* 5(7):1715-22, 7/1999. PMID: 10430074.
76. Ke LD, Adler-Storthz K, Mitchell MF, **Clayman GL**, Chen Z. Expression of human papillomavirus E7 mRNA in human oral and cervical neoplasia and cell lines. *Oral Oncol* 35(4):415-20, 7/1999. PMID: 10645408.
77. Garden AS, Glisson BS, Ang KK, Morrison WH, Lippman SM, Byers RM, Geara F, **Clayman GL**, Shin DM, Callender DL, Khuri FR, Goepfert H, Hong WK, Peters LJ. Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. *J Clin Oncol* 17(8):2390-5, 8/1999. PMID: 10561301.
78. El-Naggar AK, Lai S, **Clayman GL**, Zhou JH, Tucker SA, Myers J, Luna MA, Benedict WF. Expression of p16, Rb, and cyclin D1 gene products in oral and laryngeal squamous carcinoma: biological and clinical implications. *Hum Pathol* 30(9):1013-8, 9/1999. PMID: 10492034.
79. Byers RM, **Clayman GL**, McGill D, Andrews T, Kare RP, Roberts DB, Goepfert H. Selective neck dissections for squamous carcinoma of the upper aerodigestive tract: patterns of regional failure. *Head Neck* 21(6):499-505, 9/1999. PMID: 10449664.
80. Papadimitrakopoulou VA, **Clayman GL**, Shin DM, Myers JN, Gillenwater AM, Goepfert H, El-Naggar AK, Lewin JS, Lippman SM, Hong WK. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. *Arch Otolaryngol Head Neck Surg* 125(10):1083-9, 10/1999. PMID: 10522499.
81. El-Naggar AK, Lai S, Tucker SA, **Clayman GL**, Goepfert H, Hong WK, Huff V. Frequent loss of imprinting at the IGF2 and H19 genes in head and neck squamous carcinoma. *Oncogene* 18(50):7063-9, 11/1999. PMID: 10597307.
82. Sturgis EM, Castillo EJ, Li L, Zheng R, Eicher SA, **Clayman GL**, Strom SS, Spitz MR, Wei Q. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. *Carcinogenesis* 20(11):2125-9, 11/1999. PMID: 10545415.
83. **Clayman GL**, El-Naggar AK, Lippman SM, Henderson YC, Frederick MJ, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Brusio P, Goepfert H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. *J Clin Oncol Classic Papers and Current Comments* 17(3):849-860, 1999.
84. **Clayman GL**. Developing gene therapy for head and neck cancer communicating bench to bedside. *Acta Otorhinolaryngol Belg* 53(3):189, 1999. PMID: 10635390.
85. Spring, Nakashima T, Frederick MJ, Henderson Y, **Clayman GL**. Identification and cDNA cloning of headpin, a novel differentially expressed serpin that maps to chromosome 18q. *Biochem Biophys Res Commun* 264:299-304, 1999.
86. DeMonte F, Ginsberg LE, **Clayman GL**. Primary malignant tumors of the sphenoidal sinus. *Neurosurgery* 46(5):1084-91; discussion 1091-2, 5/2000. PMID: 10807240.
87. Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, Lewis DE, El-Naggar AK, **Clayman GL**. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. *Am J Pathol* 156(6):1937-50, 6/2000. PMID: 10854217.
88. Nakashima T, Pak SC, Silverman GA, Spring PM, Frederick MJ, **Clayman GL**. Genomic cloning, mapping, structure and promoter analysis of HEADPIN, a serpin which is down-regulated in head and neck cancer cells. *Biochim Biophys Acta* 1492(2-3):441-6, 7/2000. PMID: 11004515.

89. Henderson YC, Breau RL, Liu TJ, **Clayman GL**. Telomerase activity in head and neck tumors after introduction of wild-type p53, p21, p16, and E2F-1 genes by means of recombinant adenovirus. *Head Neck* 22(4):347-54, 7/2000. PMID: 10862017.
90. Nakashima T, **Clayman GL**. Antisense inhibition of cyclin D1 in human head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 126(8):957-61, 8/2000. PMID: 10922227.
91. Nakashima T, Hudson JM, **Clayman GL**. Antisense inhibition of vascular endothelial growth factor in human head and neck squamous cell carcinoma. *Head Neck* 22(5):483-8, 8/2000. PMID: 10897108.
92. Clifford JL, Menter DG, Yang X, Walch E, Zou C, **Clayman GL**, Schaefer TS, El-Naggar AK, Lotan R, Lippman SM. Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin. *Cancer Epidemiol Biomarkers Prev* 9(9):993-7, 9/2000. PMID: 11008921.
93. Hong FD, **Clayman GL**. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. *Cancer Res* 60(23):6551-6, 12/2000. PMID: 11118031.
94. Henderson YC, **Clayman GL**. An effective method for removing ribosomal RNA during mRNA purification. *Methods Cell Sci* 22(4):253-5, 2000. PMID: 11549937.
95. Shin, Mao L, Papadimitrakopoulou VM, **Clayman GL**, El-Naggar AK, Shin HJ, Lee JJ, Lee JS, Gillenwater A, Myers J, Lippman SM, Hittelman WN, Hong WK. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. *J Natl Cancer Inst* 92(1):69-73, 2000.
96. Duvic, Helekar B, Schulz C, Cho M, DiSepio D, Hager C, Dimao D, Hazarika P, Jackson B, Breuer-McHam J, Young J, **Clayman GL**, Lippman SM, Chandraratna RAS, Robinson NA, Deucher A, Eckert RL, Nagpal S. Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible Gene-3, is decreased in psoriasis and skin cancer. *Clin Cancer Res* 6:3249-3259, 2000.
97. **Clayman GL**, Johnson CJ, 2nd, Morrison W, Ginsberg L, Lippman SM. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. *Arch Otolaryngol Head Neck Surg* 127(2):135-9, 2/2001. PMID: 11177029.
98. El-Naggar AK, Lai S, **Clayman GL**, Mims B, Lippman SM, Coombes M, Luna MA, Lozano G. p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. *Carcinogenesis* 22(5):729-35, 5/2001. PMID: 11323391.
99. Yasumatsu R, Nakashima T, Azuma K, Hirakawa N, Kuratomi Y, Tomita K, Cataltepe S, Silverman GA, **Clayman GL**, Komiyama S. SCCA1 expression in T-lymphocytes peripheral to cancer cells is associated with the elevation of serum SCC antigen in squamous cell carcinoma of the tongue. *Cancer Lett* 167(2):205-13, 6/2001. PMID: 11369142.
100. Frederick MJ, **Clayman GL**. Chemokines in cancer. *Expert Rev Mol Med* 2001:1-18, 7/2001. PMID: 14585143.
101. Guan B, Yue P, **Clayman GL**, Sun SY. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. *J Cell Physiol* 188(1):98-105, 7/2001. PMID: 11382926.
102. Nakashima T, Sun SY, Lotan R, Fujiwara T, Yasumatsu R, Komiyama S, **Clayman GL**. All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. *Laryngoscope* 111(8):1459-64, 8/2001. PMID: 11568584.
103. Liu Y, Gilcrease MZ, Henderson Y, Yuan XH, **Clayman GL**, Chen Z. Expression of protease-activated receptor 1 in oral squamous cell carcinoma. *Cancer Lett* 169(2):173-80, 8/2001. PMID: 11431106.
104. Ahmadi MA, Prieto VG, **Clayman GL**, Ginsberg LE, Esmaeli B. Lymphoepitheliomalike carcinoma of the orbit. *Arch Ophthalmol* 119(8):1206-8, 8/2001. PMID: 11483092.
105. El-Naggar AK, Mao L, Staerkel G, Coombes MM, Tucker SL, Luna MA, **Clayman GL**, Lippman S, Goepfert H. Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. *J Mol Diagn* 3(4):164-70, 11/2001. PMID: 11687600.
106. Shin, Khuri FR, Murphy B, Garden AS, **Clayman GL**, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater G, Ang KK, Lippman

- SM, Goepfert H, Hong WK. Combined interferon- $\mu$ , 13-cis-reinoic acid and  $\mu$ -tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. . J Clin Oncol 19:3010-17, 2001.
107. Shin, Donato NJ, Perez-Soler R, Shin HJC, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, **Clayman GL**, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor targeted therapy with c225 and cisplatin in patients with head and neck cancer. . Clin Cancer Res 7(5):1204-13, 2001.
  108. Shin, Khuri FR, Glisson BS, Ginsberg L, Papadimitrakopoulou VM, **Clayman GL**, Lee JJ, Ang KK, Lippman SM, Hong WK. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. . Cancer Bulletin 91(7):1316-1323, 2001.
  109. Shin DM, Glisson BS, Khuri FR, Clifford JL, **Clayman GL**, Benner SE, Forastiere AA, Ginsberg L, Liu D, Lee JJ, Myers J, Goepfert H, Lotan R, Hong WK, Lippman SM. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol 20(2):364-70, 1/2002. PMID: 11786562.
  110. Eicher SA, **Clayman GL**, Myers JN, Gillenwater AM. A prospective study of intraoperative lymphatic mapping for head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg 128(3):241-6, 3/2002. PMID: 11886337.
  111. Ng RL, Beahm E, **Clayman GL**, Hassenbusch SJ, Miller MJ. Simultaneous reconstruction of the posterior pharyngeal wall and cervical spine with a free vascularized fibula osteocutaneous flap. Plast Reconstr Surg 109(4):1361-5, 4/2002. PMID: 11964992.
  112. Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz E, Papadimitrakopoulou V, Feng L, Francisco M, Garden A, Kies MS, Myers J, **Clayman GL**, Hong WK. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 95(2):322-30, 7/2002. PMID: 12124833.
  113. Clifford JL, Walch E, Yang X, Xu X, Alberts DS, **Clayman GL**, El-Naggar AK, Lotan R, Lippman SM. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res 8(7):2067-72, 7/2002. PMID: 12114405.
  114. Zhang X, Liu Y, Gilcrease MZ, Yuan XH, **Clayman GL**, Adler-Storthz K, Chen Z. A lymph node metastatic mouse model reveals alterations of metastasis-related gene expression in metastatic human oral carcinoma sublines selected from a poorly metastatic parental cell line. Cancer 95(8):1663-72, 10/2002. PMID: 12365014.
  115. El-Naggar AK, Kim HW, **Clayman GL**, Coombes MM, Le B, Lai S, Zhan F, Luna MA, Hong WK, Lee JJ. Differential expression profiling of head and neck squamous carcinoma: significance in their phenotypic and biological classification. Oncogene 21(53):8206-19, 11/2002. PMID: 12444558.
  116. Robbins, **Clayman GL**, Levine PA, Medina J, Sessions R, Shaha A, Som P, Wolf G. Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery. . Arch Otol Head and Neck Surg 128(7):751-8, 2002.
  117. Yasumatsu R, Nakashima T, Kuratomi Y, Hirakawa N, Azuma K, Tomita K, Cataltepe S, Silverman GA, **Clayman GL**, Komiyama S. Serum squamous cell carcinoma antigen is a useful biologic marker in patients with inverted papillomas of the sinonasal tract. Cancer 94(1):152-8, 2002. PMID: 11815971.
  118. Jayakumar A, Kang Y, Frederick MJ, Pak SC, Henderson Y, Holton PR, Mitsudo K, Silverman GA, EL-Naggar AK, Brömme D, **Clayman GL**. Inhibition of the cysteine proteinases cathepsins K and L by the serpin headpin (SERPINB13): a kinetic analysis. Arch Biochem Biophys 409(2):367-74, 1/2003. PMID: 12504904.
  119. **Clayman GL**, el-Baradie TS. Medullary thyroid cancer. Otolaryngol Clin North Am 36(1):91-105, 2/2003. PMID: 12803011.
  120. Mitsudo K, Jayakumar A, Henderson Y, Frederick MJ, Kang Y, Wang M, El-Naggar AK, **Clayman GL**. Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Biochemistry 42(13):3874-81, 4/2003. PMID: 12667078.

121. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, **Clayman GL**, Hong WK, Kumar R. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). *Mol Cancer Ther* 2(4):345-51, 4/2003. PMID: 12700278.
122. Ferlito A, Rinaldo A, Robbins KT, Leemans CR, Shah JP, Shaha AR, Andersen PE, Kowalski LP, Pellitteri PK, **Clayman GL**, Rogers SN, Medina JE, Byers RM. Changing concepts in the surgical management of the cervical node metastasis. *Oral Oncol* 39(5):429-35, 7/2003. PMID: 12747966.
123. Gonzalez HE, Gujrati M, Frederick M, Henderson Y, Arumugam J, Spring PW, Mitsudo K, Kim HW, **Clayman GL**. Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. *Arch Otolaryngol Head Neck Surg* 129(7):754-9, 7/2003. PMID: 12874078.
124. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, **Clayman GL**, Morrison WH, Liu DD, Blumenschein G, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. *Cancer* 98(10):2214-23, 11/2003. PMID: 14601092.
125. Barker JL, Glisson BS, Garden AS, El-Naggar AK, Morrison WH, Ang KK, Chao KS, **Clayman GL**, Rosenthal DI. Management of nonsinonasal neuroendocrine carcinomas of the head and neck. *Cancer* 98(11):2322-8, 12/2003. PMID: 14635065.
126. Coombes MM, Briggs KL, Bone JR, **Clayman GL**, El-Naggar AK, Dent SY. Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation. *Oncogene* 22(55):8902-11, 12/2003. PMID: 14654786.
127. Bolshakov S, Walker CM, Strom SS, Selvan MS, **Clayman GL**, El-Naggar A, Lippman SM, Kripke ML, Ananthaswamy HN. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. *Clin Cancer Res* 9(1):228-34, 2003. PMID: 12538474.
128. Rosenthal, Barker JL, El-Naggar AK, Glisson BS, Kies MS, Diaz EM, **Clayman GL**, Demonte F, Selek U, Morrison WM, Ang KK, Garden AS. Sinonasal carcinoma with neuroendocrine differentiation: patterns of failure according to histologic phenotype. *Int J Radiat Oncol Biol Phys.* 57((2 Suppl)):S248-9, 2003.
129. Yang Z, Bagheri-Yarmand R, Wang RA, Adam L, Papadimitrakopoulou VV, **Clayman GL**, El-Naggar A, Lotan R, Barnes CJ, Hong WK, Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. *Clin Cancer Res* 10(2):658-67, 1/2004. PMID: 14760089.
130. Jayakumar A, Cataltepe S, Kang Y, Frederick MJ, Mitsudo K, Henderson Y, Crawford SE, Silverman GA, **Clayman GL**. Production of serpins using baculovirus expression systems. *Methods* 32(2):177-84, 2/2004. PMID: 14698630.
131. Johnson FM, Garden A, Palmer JL, Kies M, **Clayman GL**, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. *Cancer* 100(5):991-8, 3/2004. PMID: 14983495.
132. **Clayman GL**, Gonzalez HE, El-Naggar A, Vassilopoulou-Sellin R. Parathyroid carcinoma: evaluation and interdisciplinary management. *Cancer* 100(5):900-5, 3/2004. PMID: 14983483.
133. Jayakumar A, Kang Y, Mitsudo K, Henderson Y, Frederick MJ, Wang M, El-Naggar AK, Marx UC, Briggs K, **Clayman GL**. Expression of LEKTI domains 6-9' in the baculovirus expression system: recombinant LEKTI domains 6-9' inhibit trypsin and subtilisin A. *Protein Expr Purif* 35(1):93-101, 5/2004. PMID: 15039071.
134. Busaidy NL, Jimenez C, Habra MA, Schultz PN, El-Naggar AK, **Clayman GL**, Asper JA, Diaz EM, Evans DB, Gagel RF, Garden A, Hoff AO, Lee JE, Morrison WH, Rosenthal DI, Sherman SI, Sturgis EM, Waguespack SG, Weber RS, Wirfel K, Vassilopoulou-Sellin R. Parathyroid carcinoma: a 22-year experience. *Head Neck* 26(8):716-26, 8/2004. PMID: 15287039.
135. Raghunath M, Tontsidou L, Oji V, Aufenvenne K, Schürmeyer-Horst F, Jayakumar A, Ständer H, Smolle J, **Clayman GL**, Traupe H. SPINK5 and Netherton syndrome: novel



- mutations, demonstration of missing LEKTI, and differential expression of transglutaminases. *J Invest Dermatol* 123(3):474-83, 9/2004. PMID: 15304086.
136. Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D, **Clayman GL**, El-Naggar AK. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. *Clin Cancer Res* 10(19):6586-97, 10/2004. PMID: 15475448.
  137. Shellenberger TD, Wang M, Gujrati M, Jayakumar A, Strieter RM, Burdick MD, Ioannides CG, Efferson CL, El-Naggar AK, Roberts D, **Clayman GL**, Frederick MJ. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemotactic factor for immature dendritic cells. *Cancer Res* 64(22):8262-70, 11/2004. PMID: 15548693.
  138. Robbins KT, Ferlito A, Suárez C, Brizel DM, Bradley PJ, Pellitteri PK, **Clayman GL**, Kowalski LP, Genden EM, Rinaldo A. Is there a role for selective neck dissection after chemoradiation for head and neck cancer? *J Am Coll Surg* 199(6):913-6, 12/2004. PMID: 15555975.
  139. Rosenthal DI, Barker JL, El-Naggar AK, Glisson BS, Kies MS, Diaz EM, **Clayman GL**, Demonte F, Selek U, Morrison WH, Ang KK, Chao KS, Garden AS. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. *Cancer* 101(11):2567-73, 12/2004. PMID: 15517582.
  140. **Clayman GL**, Lee JJ, Holsinger FC, Zhou X, Duvic M, El-Naggar AK, Prieto VG, Altamirano E, Tucker SL, Strom SS, Kripke ML, Lippman SM. Mortality risk from squamous cell skin cancer. *J Clin Oncol* 23(4):759-65, 2/2005. PMID: 15681519.
  141. Genden EM, Rinaldo A, Shaha AR, **Clayman GL**, Werner JA, Suárez C, Ferlito A. Treatment considerations for head and neck cancer in the elderly. *J Laryngol Otol* 119(3):169-74, 3/2005. PMID: 15845185.
  142. Nakashima T, Kuratomi Y, Yasumatsu R, Masuda M, Koike K, Umezaki T, **Clayman GL**, Nakagawa T, Komune S. The effect of cyclin D1 overexpression in human head and neck cancer cells. *Eur Arch Otorhinolaryngol* 262(5):379-83, 5/2005. e-Pub 9/2004. PMID: 15368064.
  143. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, Barnetson RA, Anton-Culver H, Peel D, Ziogas A, Lin D, Miao X, Sun T, Ostrander EA, Stanford JL, Langlois M, Chan JM, Yuan J, Harris CC, Bowman ED, **Clayman GL**, Lippman SM, Lee JJ, Zheng W, Balmain A. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. *Carcinogenesis* 26(8):1368-73, 8/2005. e-Pub 3/2005. PMID: 15802297.
  144. Moore BA, Weber RS, Prieto V, El-Naggar A, Holsinger FC, Zhou X, Lee JJ, Lippman S, **Clayman GL**. Lymph node metastases from cutaneous squamous cell carcinoma of the head and neck. *Laryngoscope* 115(9):1561-7, 9/2005. PMID: 16148695.
  145. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, **Clayman GL**, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. *Int J Radiat Oncol Biol Phys* 63(3):717-24, 11/2005. PMID: 16199307.
  146. Schechter NM, Choi EJ, Wang ZM, Hanakawa Y, Stanley JR, Kang Y, **Clayman GL**, Jayakumar A. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI). *Biol Chem* 386(11):1173-84, 11/2005. PMID: 16307483.
  147. Shellenberger TD, Mazumdar A, Henderson Y, Briggs K, Wang M, Chattopadhyay C, Jayakumar A, Frederick M, **Clayman GL**. Headpin: a serpin with endogenous and exogenous suppression of angiogenesis. *Cancer Res* 65(24):11501-9, 12/2005. PMID: 16357159.
  148. Wang LE, Xiong P, Strom SS, Goldberg LH, Lee JE, Ross MI, Mansfield PF, Gershenwald JE, Prieto VG, Cormier JN, Duvic M, **Clayman GL**, Weber RS, Lippman SM, Amos CI, Spitz MR, Wei Q. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. *J Natl Cancer Inst* 97(24):1822-31, 12/2005. PMID: 16368944.
  149. Yu P, **Clayman GL**, Walsh GL. Human tracheal reconstruction with a composite radial forearm free flap and prosthesis. *Ann Thorac Surg* 81(2):714-6, 2/2006. PMID: 16427881.

150. Wei WI, Ferlito A, Rinaldo A, Gourin CG, Lowry J, Ho WK, Leemans CR, Shaha AR, Suárez C, **Clayman GL**, Robbins KT, Bradley PJ, Silver CE. Management of the N0 neck--reference or preference. *Oral Oncol* 42(2):115-22, 2/2006. e-Pub 6/2005. PMID: 15979931.
151. Artopoulos, II, Lemon JC, **Clayman GL**, Chambers MS. Stent fabrication for graft immobilization following wide surgical excision of myofibroblastic sarcoma of the buccal mucosa: a clinical report. *J Prosthet Dent* 95(4):280-5, 4/2006. PMID: 16616124.
152. Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA, Jr, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, **Clayman GL**, Hittelman WN, Hong WK, Lotan R. Fenretinide activity in retinoid-resistant oral leukoplakia. *Clin Cancer Res* 12(10):3109-14, 5/2006. PMID: 16707609.
153. Komatsu N, Suga Y, Saijoh K, Liu AC, Khan S, Mizuno Y, Ikeda S, Wu HK, Jayakumar A, **Clayman GL**, Shirasaki F, Takehara K, Diamandis EP. Elevated Human Tissue Kallikrein Levels in the Stratum Corneum and Serum of Peeling Skin Syndrome-Type B Patients Suggests an Over-desquamation of Corneocytes. *J Invest Dermatol* 126(10):2338-42, 6/2006. PMID: 16778802.
154. Hachem JP, Wagberg F, Schmutz M, Crumrine D, Lissens W, Jayakumar A, Houben E, Mauro TM, Leonardsson G, Brattsand M, Egelrud T, Roseeuw D, **Clayman GL**, Feingold KR, Williams ML, Elias PM. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. *J Invest Dermatol* 126(7):1609-21, 7/2006. e-Pub 4/2006. PMID: 16601670.
155. Elias PM, Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, **Clayman GL**, Fisher SG, Forastiere AA, Harrison LB, Lefebvre JL, Leupold N, List MA, O'Malley BO, Patel S, Posner MR, Schwartz MA, Wolf GT. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. *J Clin Oncol* 24(22):3693-704, 8/2006. e-Pub 7/2006. PMID: 16832122.
156. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, **Clayman GL**, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. *J Clin Oncol* 24(25):4163-9, 9/2006. PMID: 16943532.
157. Ferlito A, Rinaldo A, Silver CE, Gourin CG, Shah JP, **Clayman GL**, Kowalski LP, Shaha AR, Robbins KT, Suárez C, Leemans CR, Ambrosch P, Medina JE, Weber RS, Genden EM, Pellitteri PK, Werner JA, Myers EN. Elective and therapeutic selective neck dissection. *Oral Oncol* 42(1):14-25, 2006. e-Pub 6/2005. PMID: 15979381.
158. Wang LE, Hsu TC, Xiong P, Strom SS, Duvic M, Clayman **GL**, Weber RS, Lippman SM, Goldberg LH, Wei Q. 4-Nitroquinoline-1-Oxide-Induced Mutagen Sensitivity and Risk of Nonmelanoma Skin Cancer: A Case-Control Analysis. *J Invest Dermatol* 127(1):196-205, 1/2007. PMID: 16841033.
159. Oki Y, Saijoh K, Otsuki N, **Clayman GL**. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. *Clinic Cancer Research* 109(1):77-83, 1/2007. PMID: 17133412.
160. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, **Clayman GL**, Medeiros LJ, Kwak LW, Srivastava PK, Younes A. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. *Cancer* 109(1):77-83, 1/2007. PMID: 17133412.
161. Borgoño CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, **Clayman GL**, Sotiropoulou G, Diamandis EP. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. *J Biol Chem* 282(6):3640-52, 2/2007. e-Pub 12/2006. PMID: 17158887.
162. Henderson YC, Frederick MJ, Jayakumar A, Choi Y, Wang MT, Kang Y, Evans R, Spring PM, Uesugi M, **Clayman GL**. Human LBP-32/MGR is a repressor of the P450scc in human choriocarcinoma cell line JEG-3. *Placenta* 28(2-3):152-60, 2/2007. PMID: 16730372.
163. Komatsu N, Saijoh K, Otsuki N, Kishi T, Micheal IP, Obiezu CV, Borgono CA, Takehara K, Jayakumar A, Wu HK, **Clayman GL**, Diamandis EP. Proteolytic processing of human growth hormone by multiple tissue kallikreins and regulation by the serine protease inhibitor Kazal-Type5 (SPINK5) protein. *Clin Chim Acta* 377(1-2):228-36, 2/2007. e-Pub 10/2006. PMID: 17140555.

164. Shellenberger T, Fornage B, Ginsberg L, **Clayman GL**. Transoral resection of thyroid cancer metastasis to lateral retropharyngeal nodes. *Head Neck* 29(3):258-66, 3/2007. PMID: 17022089.
165. Brewster AM, Lee JJ, Clayman **GL**, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM. Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. *J Clin Oncol* 25(15):1974-8, 5/2007. PMID: 17513803.
166. Henderson YC, Fredrick MJ, **Clayman GL**. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors. *Arch Otolaryngol Head Neck Surg* 133(8):810-5, 8/2007. PMID: 17709622.
167. Komatsu N, Saijoh K, Jayakumar A, **Clayman GL**, Tohyama M, Suga Y, Mizuno Y, Tsukamoto K, Taniuchi K, Takehara K, Diamandis EP. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients. *J Invest Dermatol* 128(5):1148-59. e-Pub 11/2007. PMID: 17989726.
168. Wang LE, Li C, Strom SS, Goldberg LH, Brewster A, Guo Z, Qiao Y, **Clayman GL**, Lee JJ, El-Naggar AK, Prieto VG, Duvic M, Lippman SM, Weber RS, Kripke ML, Wei Q. Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression. *Clin Cancer Res* 13(21):6532-9, 11/2007. PMID: 17975167.
169. Elliott DD, Sherman SI, Busaidy NL, Williams MD, Santarpia L, **Clayman GL**, El-Naggar AK. Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification. *Hum Pathol* 39(1):15-20, 1/2008. e-Pub 10/2007. PMID: 17949783.
170. Ahn SH, Henderson Y, Kang Y, Chattopadhyay C, Holton P, Wang M, Briggs K, **Clayman GL**. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. *Arch Otolaryngol Head Neck Surg* 134(2):190-7, 2/2008. PMID: 18283163.
171. Henderson YC, Frederick MJ, Wang MT, Hollier LM, **Clayman GL**. LBP-1b, LBP-9, and LBP-32/MGR detected in syncytiotrophoblasts from first-trimester human placental tissue and their transcriptional regulation. *DNA Cell Biol* 27(2):71-9, 2/2008. PMID: 18004979.
172. Shellenberger TD, Williams MD, **Clayman GL**, Kumar AJ. Parotid Gland Oncocytosis: CT findings with histopathologic correlation. *SJNR AM J. Neuroradiol.* 29(4):734-6, 4/2008. PMID: 18272563.
173. Schwartz DL, Rana V, Shaw S, Yazbeck C, Ang KK, Morrison WH, Rosenthal DI, Hoff A, Evans DB, **Clayman GL**, Garden AS, Sherman SI. Postoperative radiotherapy for advanced medullary thyroid cancer--local disease control in the modern era. *Head Neck* 30(7):883-8, 7/2008. PMID: 18213725.
174. Chattopadhyay C, El-Naggar AK, Williams MD, **Clayman GL**. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. *Head Neck* 30(8):991-1000, 8/2008. PMID: 18327775.
175. Henderson YC, Ahn SH, Kang Y, **Clayman GL**. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. *Clin Cancer Res* 14(15):4908-14, 8/2008. PMID: 18676765.
176. Hessel A, Chalian AA, **Clayman GL**. Surgical management of recurrent thyroid cancer. *Neuroimaging Clin N Am* 18(3):517-25, viii, 8/2008. PMID: 18656032.
177. Kupferman ME, Weinstock YE, Santillan AA, Mishra A, Roberts D, **Clayman GL**, Weber RS. Predictors of level V metastasis in well-differentiated thyroid cancer. *Head Neck* 30(11):1469-74, 11/2008. PMID: 18704973.
178. Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Ciepely KM, **Clayman GL**. High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. *Clin Cancer Res* 15(2):485-91, 1/2009. PMID: 19147753.
179. Chakravarty G, Santillan AA, Galer C, Adams HP, El-Naggar AK, Jasser SA, Mohsin S, Mondal D, **Clayman GL**, Myers JN. Phosphorylated Insulin like growth factor-I receptor expression and its clinico-pathological significance in histologic subtypes of human thyroid cancer. *Exp Biol Med (Maywood)* 234(4):372-86, 1/2009. e-Pub 1/2009. PMID: 19176870.
180. Santarpia L, Sherman SI, Marabotti A, **Clayman GL**, El-Naggar AK. Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. *Hum Pathol* 40(6):827-33. e-Pub 2/2009. PMID: 19200582.

181. Henderson YC, Ahn SH, **Clayman GL**. Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040. *Arch Otolaryngol Head Neck Surg* 135(4):347-54, 4/2009. PMID: 19380355.
182. Waguespack SG, Sherman SI, Williams MD, **Clayman GL**, and Herzog, CE. The successful use of Sorafenib to treat pediatric papillary thyroid carcinoma. *Thyroid* 19(4):407-12, 4/2009. e-Pub 2009. PMID: 19355831.
183. Mazumdar A, Henderson YC, El-Naggar AK, Sen S, **Clayman GL**. Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. *Head Neck* 31(5):625-34, 5/2009. e-Pub 12/2008. PMCID: PMC2668723.
184. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Evans DB, Clayman G, Sherman SI, Garden AS. Postoperative External Beam Radiotherapy for Differentiated Thyroid Cancer: Outcomes and Morbidity With Conformal Treatment. *Int J Radiat Oncol Biol Phys* 74(4):1083-91, 7/2009. e-Pub 12/2008. PMCID: PMC2745400.
185. **Clayman GL**, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB, Mishra A, Sherman SI. Approach and safety of comprehensive central compartment dissection in patients with recurrent papillary thyroid carcinoma. *Head Neck* 31(9):1152-63, 9/2009. e-Pub 4/2009. PMID: 19360746.
186. Williams MD, Suliburk JW, Staerkel GA, Busaidy NL, **Clayman GL**, Evans DB, Perrier ND. Clinical Significance of Distinguishing Between Follicular Lesion and Follicular Neoplasm in Thyroid Fine-Needle Aspiration Biopsy. *Ann Surg Oncol* 16(11):3146-53, 11/2009. e-Pub 9/2009. PMID: 19727961.
187. Nemunaitis J, **Clayman GL**, Agarwala S, Hrushesky W. Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck. *Clin Cancer Res* 15(24):7719-7725, 12/2009. PMID: 19996201.
188. Wang LE, Hu Z, Sturgis EM, Spitz MR, Strom SS, Amos CI, Guo Z, Qiao Y, Gillenwater AM, Myers JN, **Clayman GL**, Weber RS, El-Naggar AK, Mao L, Lippman SM, Hong WK, Wei Q. Reduced DNA Repair Capacity for Removing Tobacco Carcinogen-Induced DNA Adducts Contributes to Risk of Head and Neck Cancer but not Tumor Characteristics. *Clin Cancer Res* 16(2):764-74, 1/2010. e-Pub 1/2010. PMCID: PMC2848391.
189. Santarpia L, Myers JN, Sherman SI, Trimarchi F, **Clayman GL**, El-Naggar AK. Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma. *Cancer* 116(12):2974-83, 6/2010. PMID: 20564403.
190. Bhatia A, Rao A, Ang KK, Garden AS, Morrison WH, Rosenthal DI, Evans DB, **Clayman G**, Sherman SI, Schwartz DL. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. *Head Neck* 32(7):829-36, 7/2010. e-Pub 11/2009. PMID: 19885924.
191. Henderson YC, Chen Y, Frederick MJ, Lai SY, **Clayman GL**. MEK Inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. *Mol Cancer Ther* 9(7):1968-76, 7/2010. e-Pub 6/2010. PMCID: PMC2935263.
192. Yu P, **Clayman GL**, Walsh GL. Long-term outcomes of microsurgical reconstruction for large tracheal defects. *Cancer* 117(4):802-8, 2/2011. e-Pub 9/2010. PMID: 20872878.
193. Frederick MJ, VanMeter AJ, Gadhikar MA, Henderson YC, Yao H, Pickering CC, Williams MD, El-Naggar AK, Sandulache V, Tarco E, Myers JN, Clayman GL, Liotta LA, Petricoin EF, Calvert VS, Fodale V, Wang J, Weber RS. Phosphoproteomic Analysis of Signaling Pathways in Head and Neck Squamous Cell Carcinoma Patient Samples. *Am J Pathol* 178(2):548-71, 2/2011. PMCID: PMC3070553.
194. Moreno MA, Agarwal G, de Luna R, Siegel ER, Sherman SI, Edeiken-Monroe BS, Clayman GL. Preoperative lateral neck ultrasonography as a long-term outcome predictor in papillary thyroid cancer. *Arch Otolaryngol Head Neck Surg* 137(2):157-62, 2/2011. PMID: 21339402.
195. Andrews GA, Kwon M, **Clayman G**, Edeiken B, Kupferman ME. Technical refinement of ultrasound-guided transoral resection of parapharyngeal/retropharyngeal thyroid carcinoma metastases. *Head Neck* 33(2):166-70, 2/2011. PMID: 20848435.
196. Zhao M, Sano D, Pickering CR, Jasser SA, Henderson YC, Clayman GL, Sturgis EM, Ow TJ, Lotan R, Carey TE, Sacks PG, Grandis JR, Sidransky D, Heldin NE, Myers JN. Assembly And Initial Characterization Of A Panel Of 85 Genomically Validated Cell Lines From Diverse

- Head And Neck Tumor Sites. *Clin Cancer Res* 17(23):7248-64, 12/2011. e-Pub 8/2011. PMID: PMC3229662.
197. **Clayman GL**, Agarwal G, Edeiken BS, Waguespack SG, Roberts DB, Sherman SI. Long term outcome of comprehensive central compartment dissection in patients with recurrent/persistent papillary thyroid carcinoma. *Thyroid* 21(12):1309-16, 12/2011. PMID: PMC3968954.
  198. Moreno MA, Edeiken-Monroe BS, Siegel ER, Sherman SI, Clayman GL. In papillary thyroid cancer, preoperative central neck ultrasound detects only macroscopic surgical disease, but negative findings predict excellent long-term regional control and survival. *Thyroid* 22(4):347-55, 4/2012. e-Pub 1/2012. PMID: PMC3968956.
  199. Bennett K, Heywood W, Di WL, Harper J, Clayman GL, Jayakumar A, Callard R, Mills K. The identification of a new role for LEKTI in the skin: The use of protein 'bait' arrays to detect defective trafficking of dermcidin in the skin of patients with Netherton syndrome. *J Proteomics* 75(13):3925-37, 7/2012. e-Pub 5/2012. PMID: 22588119.
  200. Morris LF, Waguespack SG, Warneke CL, Ryu H, Ying AK, Anderson BJ, Sturgis EM, Clayman GL, Lee JE, Evans DB, Grubbs EG, Perrier ND. Long-term follow-up data may help manage patient and parent expectations for pediatric patients undergoing thyroidectomy. *Surgery* 152(6):1165-71, 12/2012. PMID: 23158186.
  201. Ahn SH, Henderson YC, Williams MD, Lai SY, **Clayman GL**. Detection of Thyroid Cancer Stem Cells in Papillary Thyroid Carcinoma. *J Clin Endocrinol Metab* 99(2):536-44, 2/2014. e-Pub 12/2013. PMID: PMC3913805.
  202. Henderson YC, Toro-Serra R, Chen Y, Ryu J, Frederick MJ, Zhou G, Gallick GE, Lai SY, **Clayman GL**. Src inhibitors in suppression of papillary thyroid carcinoma growth. *Head Neck* 36(3):375-384, 3/2014. e-Pub 6/2013. PMID: PMC4401074.
  203. Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, **Clayman GL**, Rohren EM. Measuring the extent of total thyroidectomy for differentiated thyroid carcinoma using radioactive iodine imaging: relationship with serum thyroglobulin and clinical outcomes. *JAMA Otolaryngol Head Neck Surg* 140(5):410-5, 5/2014. PMID: 24700275.
  204. Fornage BD, Edeiken BS, **Clayman GL**. Use of transoral sonography with an endocavitary transducer in diagnosis, fine-needle aspiration biopsy, and intraoperative localization of retropharyngeal masses. *AJR Am J Roentgenol* 202(5):W481-6, 5/2014. PMID: 24758683.
  205. Tufano RP, **Clayman G**, Heller KS, Inabnet WB, Kebebew E, Shaha AR, Steward D, Tuttle RM. Management of Recurrent/Persistent Nodal Disease in Patients with Differentiated Thyroid Cancer: a Critical Review of the Risks and Benefits of Surgical Intervention versus Active Surveillance. *Thyroid* 25(1):15-27. e-Pub 9/2014. PMID: 25246079.
  206. Su SY, Milas ZL, Bhatt N, Roberts D, **Clayman GL**. Well differentiated thyroid cancer with aerodigestive tract invasion: Long-term control and functional outcomes. *Head Neck*. e-Pub 9/2014. PMID: 25204531.
  207. Pickering CR, Zhou JH, Lee JJ, Drummond JA, Peng SA, Saade RE, Tsai KY, Curry JL, Tetzlaff MT, Lai SY, Yu J, Muzny DM, Doddapaneni H, Shinbrot E, Covington KR, Zhang J, Seth S, Caulin C, **Clayman GL**, El-Naggar AK, Gibbs RA, Weber RS, Myers JN, Wheeler DA, Frederick MJ. Mutational landscape of aggressive cutaneous squamous cell carcinoma. *Clin Cancer Res* 20(24):6582-92, 12/2014. e-Pub 10/2014. PMID: PMC4367811.
  208. Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and Characterization of Six New Human Papillary Thyroid Carcinoma Cell Lines. *J Clin Endocrinol Metab* 100(2):jc20142624, 2/2015. e-Pub 11/2014. PMID: PMC4318904.
  209. Henderson YC, Ahn SH, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, **Clayman GL**. Development and characterization of six new human papillary thyroid carcinoma cell lines. *J Clin Endocrinol Metab* 100(2):E243-52, 2015 Feb, 2/2015. e-Pub 11/2014. PMID: PMC4318904.
  210. **Clayman GL**. Local treatment of differentiated thyroid carcinoma. *Clin Adv Hematol Oncol* 13 (4 Suppl 4)(4 Suppl 4):6-8, 4/2015. PMID: 26430869.

211. Shah JP, **Clayman GL**, Wirth LJ. New and emerging therapeutic options for thyroid carcinoma. *Clin Adv Hematol Oncol* 13(4 Suppl 4):3-17, 1; quiz 2 p following 18, 4/2015. PMID: 25856096.
212. **Clayman GL**, Wirth LJ. New and emerging therapeutic options for thyroid carcinoma: q&a discussion. *Clin Adv Hematol Oncol* 13 Suppl 4(4)(4 Suppl 4):6-9, 4/2015. PMID: 26430871.
213. Jayakumar A, Frederick M, Shellenberger T, Henderson Y, Kang Y, et al. Molecular and Biochemical Properties of Lympho-Epithelial Kazal-Type-Inhibitor (LEKTI). *MOJ Proteomics Bioinform* 2(4):00053, 8/2015.
214. George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY, **Clayman GL**. Association of TERT Promoter Mutation, but Not BRAF Mutation, with Increased Mortality in PTC. *J Clin Endocrinol Metab* 100(12):E1550-E1559. e-Pub 10/2015. PMID: 26461266.
215. Shellenberger T, Frederick MJ, Henderson Y, Kang Y, Jayakumar K, et al. Expression of LEKTI Correlates With PNI and LVI In SCC of the Oral Tongue and Mechanism of LEKTI Loss in HNSCC. *MOJ Proteomics Bioinform* 2(5):00060, 2015.
216. **GL Clayman**, CF Holsinger. Measuring the Extent of Total Thyroidectomy with Radioactive 123 Iodine Imaging: Relationship with Serum Thyroglobulin and Clinical Outcomes. *JAMA Otolaryngology-Head and Neck Surgery*. In Press.
217. Debnam MJ, Kwon M, Fornage B, Krishnamurthy S, Edeiken-Monroe BS, **Clayman GL**. Sonographic Evaluation of Intrathyroid Metastases. *J Ultrasound Med*. In Press.

#### Invited Articles

1. Lippman SM, Clayman GL, Huber MH, Benner SE, Hong WK. Biology and reversal of aerodigestive tract carcinogenesis. *Cancer Treat Res* 74:89-115, 1995. PMID: 7779624.
2. Breau RL, **Clayman GL**. Gene therapy for head and neck cancer. *Curr Opin Oncol* 8(3):227-31, 5/1996. PMID: 8804819.
3. **Clayman GL**, Ebihara S, Terada M, Mukai K, Goepfert H. Report of the tenth international symposium of the foundation for promotion of cancer research: Basic and clinical research in head and neck cancer. *Jpn J Clin Oncol* 27:361-368, 5/1997.
4. **Clayman GL**, Dreiling LK. Injectable modalities as local and regional strategies for head and neck cancer. *Hematol Oncol Clin North Am* 13(4):787-810, viii, 8/1999. PMID: 10494514.
5. **Clayman GL**, Dreiling L. Local delivery for gene therapy. *Curr Oncol Rep* 1(2):138-43, 1999. PMID: 11122810.
6. **Clayman GL**. The current status of gene therapy. *Semin Oncol* 27(4 Suppl 8):39-43, 8/2000. PMID: 10952437.
7. Frederick MJ, **Clayman GL**. Chemokines in cancer. *Exp Rev Mol Med* 18, 2001.
8. Grubbs EG, Rich TA, Li G, Sturgis EM, Younes MN, Myers JN, Edeiken-Monroe B, Fornage BD, Monroe DP, Staerkel GA, Williams MD, Waguespack SG, Hu MI, Cote G, Gagel RF, Cohen J, Weber RS, Anaya DA, Holsinger FC, Perrier ND, **Clayman GL**, Evans DB. Recent advances in thyroid cancer. *Curr Probl Surg* 45(3):156-250, 3/2008. PMID: 18346477.
9. Raouane M, Desmaele D, Gilbert-Sirieix M, Gueutin C, Zouhiri F, Bourgaux C, Lepeltier E, Gref R, Ben Salah R, **Clayman G**, Massaad-Massade L, Couvreur P. Synthesis, characterization, and in vivo delivery of siRNA-squalene nanoparticles targeting fusion oncogene in papillary thyroid carcinoma. *J Med Chem* 54(12):4067-76, 6/2011. e-Pub 5/2011. PMID: 21561161.
10. Williams MD, Zhang L, Elliott DD, Perrier ND, Lozano G, Clayman GL, El-Naggar AK. Differential gene expression profiling of aggressive and nonaggressive follicular carcinomas. *Hum Pathol* 42(9):1213-20, 9/2011. e-Pub 3/2011. PMID: PMC3156288.
11. Nakashima T, Yasumatsu R, Masuda M, Clayman GL, Komune S. Prognostic value of cathepsin L and its inhibitor headpin in oral squamous cell carcinoma. *J Laryngol Otol* 126(11):1134-1137, <http://journals.cambridge.org/action/displayAbstract?fromPage=online&aid=8719951>, 11/2012. e-Pub 9/2012. PMID: 22963824.

#### Editorials

1. Ferlito A, Rinaldo A, Robbins KT, Leemans CR, Shah JP, Shaha AR, Andersen PE, Kowalski LP, Pellitteri PK, **Clayman GL**, Rogers SN, Medina JE, Byers RM. Changing concepts in the surgical management of the cervical node materials. *Oral Oncol* 39:429-435, 5/2003.

**Other Articles**

N/A

**Abstracts**

N/A

**Book Chapters**

1. **Clayman GL**, Weber RS. Pharyngocutaneous Fitsula. In: Current Therapy in Otolaryngology-Head and Neck Surgery, 5. Ed(s) Gates GA. Mosby: St. Louis, 339-344, 1994.
2. **Clayman GL**, Weber RS. Cancer of the hypopharynx and cervical esophagus. In: Cancer of the Head and Neck, 3. Ed(s) MyersEN, Suen JY. WB Saunders Copmany: Philadelphia, 423-438, 1996.
3. **Clayman GL**, Lippman SM, Laramore GE, Hong WK. Head and neck cancer. In: Cancer Medicine, 4. Ed(s) Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR. Williams & Wilkins: Baltimore, 1465-1710, 1996.
4. Lippman SM, Lotan R, **Clayman GL**. Systemic Prevention and Treatment of Skin Cancer. In: Basal and squamous Cell Skin Cancer of the Head and Neck. Media: Williams and Wilkins: n/a, 1996.
5. Doughtery TM, **Clayman GL**. Airway management of srurgical patients with head and neck malignancies. In: Anesthesiology Clinics of North America. 6, 3. Ed(s) Supkis DE, Jr. WB Saunders Company: Philadelphia, 547-562, 1998.
6. **Clayman GL**, Sicard MW. Gene Therapy. In: Head and Neck Surgery Otolaryngology. 2, 2. Ed(s) Bailey BJ, Calhoun KH. Lippincott-Raven: Philadelphia, 1361-1367, 1998.
7. **Clayman GL**, Frank DK, Bruso PA. Ad-p53 Clinical trial in patients with squamous cell carcinoma of the head and neck. In: Adenoviruses: Basic Biology to Gene Therapy. Ed(s) Seth P. RG Landes Company: Austin, 279-283, 1999.
8. **Clayman GL**, Frank DK, Garden A, Hong WK. Advanced squamous cell carcinoma of the laryn. In: Head and Neck Cancer: A Multidisciplinary Approach. Ed(s) Harrison LB, Sessions RB, Hong WK. Lippincott-Raven: Philadelphia, 511-527, 1999.
9. **Clayman GL**, Frank DK, Garden A, Hong WK. Advanced squamous cell carcinoma of the larynx. In: Head and Neck Cancer: A Multidisciplinary Approach. Ed(s) Harrison LB, Sestions RB, Hong WK. Lipincott Raven: Philadelphia, 1096, 1999.
10. **Clayman GL**, Weber RS, OMalley BB. Cancer of the hypopharynx and cervical esophagus. In: Head and Neck Cancer: A Multidisciplinary Approach. Ed(s) Harrison LB, Session RB, Hong WK. Lippincott Raven: Philadelphia, 529-554, 1999.
11. Breau RL, **Clayman GL**. Gene Therapy. In: Head and Neck Cancer: A Multidisciplinary Approach. Ed(s) Harrison LB, Session RB, Hong WK. Lippincott Raven: Philadelphia, 1029-1038, 1999.
12. Lansford CD, Grenman R, Bier H, Somers DK, Kim SY, Whiteside TL, **Clayman GL**, Welkoborsky HJ, Carey TE. Head and Neck Cancers. In: Human Cell Culture, 2. Ed(s) Masters and Palsson. Kluwer Academic Publishers: Great Britain, 185-255, 1999.
13. **Clayman GL**, Dreiling LK. Injectable modalities as locan and regional strategies for head and neck cancer. In: Hematology/Oncology Clinics of North American. 13, 4. Ed(s) James M, Gaertner M, Urba SG. WB Saunders Company: Philadelphia, 787-810, 1999.
14. **Clayman GL**, Lippman SM, Laramore GE, Hong WK. Head and Neck Cancer. In: Cancer Medicine. Section 27, 5. Ed(s) Holland and Frei. Williams & Wilkins: Baltimore, 1173-1220, 2000.
15. **Clayman GL**, Douglas K. Frank, Adam S. Garden, Merrill S. Kies. Advanced Stage Cancer of the Larynx. In: Head and Neck Cancer: A Multidisciplinary Approach. 19, II. Lippincott Williams & Wilkins, 381-403, 2003.
16. **Clayman GL**, Ang K, Mies Merrill S. Cancer of the Oropharynx. In: Cancer of the Head and Neck. Chapter 14, 4, 321-332, 2003.
17. Randall L. Breau, **Clayman GL**. Gene Replacement Therapy. In: Head and Neck Cancer: A Multidisciplinary Approach, III. Lippincott Williams & Wilkins, 1018-1028, 2003.
18. Yoo G, **Clayman GL**. Gene Therapy for Patients with Head and Neck Cancer. In: Head and Neck Cancer: Emerging Perspectives. Ed(s) Ensley JF, Gutkind JS, Jacobs JR, Lippman SM. Academic Press: Orlando, 556-566, 2003.

19. El-Baradie T, **Clayman GL**. Medullary Thyroid Cancer. In: Otolaryngology Clinics of North America, 91-105, 2003.
20. Eduardo M. Diaz Jr., Erich M. Sturgis, George E. Laramore, Anita L. Sabichi, Scott M. Lippman, **Clayman GL**. Neoplasms of the Head and Neck. In: Cancer 6 Medicine. 2, Section 26 (90), 1325-1371, 2003.
21. Eicher SA, **Clayman GL**. Surgical Management of Neck Metastases. In: Pathophysiology of Nodal Metastases and Rationale for Neck Dissection. Ed(s) Jack L. Gluckman, Jonas T. Johnson. Martin Dunitz: UK, 2003.
22. **Clayman GL**, Garden A, Hong WK, Kies M. Advanced squamous cell carcinoma of the larynx. In: Head and Neck Cancer: A Multidisciplinary Approach, 2. Ed(s) Harrison LB, Session RB, Hong WK. Lippincott Raven: Philadelphia, 2004.
23. Eduardo M. Diaz Jr., Merrill S. Kies, Erich M. Sturgis, Lewis Clayman, George E. Laramore, Scott M. Lippman, **Clayman GL**. Neoplasms of the Head and Neck. In: Cancer 7 Medicine. Section 26 (79), 1131-1178, 2006.
24. Mouhammed A. Habra, Rena Vassilopoulou Sellin, **Clayman GL**. Advanced Therapy of Surgical Oncology. In: Parathyroid Carcinoma. BC Decker, Inc., 2007 in press, 2007.
25. **Clayman GL**. How to Avoid Injury to Thoracic Duct during Surgical Resection of Left Level IV Lymph Nodes. In: Pearls and Pitfalls in Head and Neck Surgery. KARGER, 56-57, 2008.
26. **Clayman GL**, TD Shellenberger. Management of Invasive Thyroid Cancer. In: Atlas of Thyroid & Parathyroid Surgery, 2008.
27. Grubbs EG, Rich TA, Li G, Sturgis EM, **Clayman GL**, et al. Recent advances in thyroid cancer. In: Curr Probl Surg. 45, 3, 156-250, 2008.
28. Hessel A, Chaliann AA, **Clayman GL**. Surgical Management of Recurrent Thyroid Cancer. In: Neuroimaging Clinics of North America. 18, 3, 517-525, 2008.
29. Randolph G. Parathyroid Carcinoma. In: Surgery of the Thyroid and Parathyroid Glands, 2nd. Elsevier/Saunders, 2012.
30. **G.L. Clayman**. Surgical Management of Recurrent/Persistent Differentiated Thyroid Cancer. In: Pearls and Pitfalls, 2nd, revised and extended. Ed(s) Claudio R., Cernea, Sao Paulo, Brazil. S. Karger, Basel: Basel, 2, 2012.
31. Myers, Eugene, Ferris, Robert, **Clayman, GL**. Technique for Completion/Reoperative Thyroidectomy. In: Masters Techniques in Otolaryngology - Head and Neck Surgery Vol. 2, 2013.
32. David Terris, William Duke, Janice Pasioka. Parathyroid Carcinoma. In: Parathyroid Surgery. Plural Publishing: San Diego, CA, 203-211, 2014. PMID: 978-1-59756-541-7.
33. Eugene N. Myers and Robert L. Ferris. Technique for Completion/Reoperative Thyroidectomy. In: Head and Neck Surgery Thyroid, Parathyroid, Salivary Glands, Paranasal Sinuses and Nasopharynx. 2. Ed(s) Eugene N. Myers and Robert L. Ferris. Wolters Kluwer Health Lippincott Williams & Wilkins: China, 139, 2014. PMID: 978-1-4511-4367-6.

#### **Books (edited and written)**

1. **Clayman GL**, Cohen JL. Ed(s) Anderson PE, Hanna E, Holsinger FC, Lydiatt WM, Schindler JS, Wax MK. Atlas of Head and Neck Surgery, 1st. ELSEVIER Saunders: Philadelphia, PA, 2011.
2. Gary L. Clayman, D.M.D., M.D., F.A.C.S. Live It. In Press.

#### **Letters to the Editor**

1. **Clayman GL**. Acute phase proteins and interleukin 6 serum level in head and neck cancer. Arch Otolaryngol Head Neck Surg 118:1366-1367, 1992.
2. Eisele D, Turfano R, **Clayman GL**, Ridge D. Consensus Statement on Central Neck Dissection Terminology and Classification for Thyroid Cancer. Archives of Otolaryngology - Head & Neck, 2009. e-Pub .
3. Ginsberg LE, **Clayman GI**, Edeiken-Monroe BS, Rohren E, Sherman SI. Not so fast on the thyroidectomy--response to Eloy, et al. AJNR Am J Neuroradiol 31(2):E30; author reply E31, 2/2010. e-Pub 1/2010. PMID: 20075083.

#### **Manuals, Teaching Aids, Other Teaching Publications**

N/A



**Other Publications**

N/A

**EDITORIAL AND REVIEW ACTIVITIES**

**Editor/Service on Editorial Board(s)**

Editorial Board, Laryngoscope, 1997-present

Editorial Board, eMedicine, 1999-present

Editorial Board, Oral Oncology, 2000-2002

Editorial Board, Frontiers in Bioscience, 2000-present

Editorial Board, Clinical Cancer Research, 2003-present

Editorial Board, Current Cancer Therapy Reviews, 2004-present

Editorial Board, Head & Neck, 2004-present

Editorial Board, Clinical Medicine, ENT, 2007

**Member of Editorial Review Board**

Specialty Editor, ASCO/Cancer.net, 2008-present

**Journal Reviewer**

Reviewer, Various, Review manuscripts for Nature Medicine, Cancer, Cancer Research, Archives of Otolaryngology/Head and Neck Surgery, Texas Medicine, Journal of Head and Neck Surgery, American Cancer Society, Journal of Clinical Immunology, New England Journal of Medicine, Frontiers in Bioscience, 1991-present

**Other Editorial and Review Activities**

N/A

**TEACHING**

**Teaching Within Current Institution -**

**Formal Teaching**

**Courses Taught**

N/A

**Training Programs**

N/A

**Other Formal Teaching**

N/A

**Supervisory Teaching**

**Committees**

**Advisory Committees**

N/A

**Supervisory Committees**

N/A

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

Graduate Research Asst., Neel Bhatt, MBBS, 1/2011-7/2012

**Postdoctoral Research Fellows**

Post-Doc Fellow, Dr. Francois Janot, 7/1993-6/1994  
Post-Doc Fellow, Dr. Frank Hong, 2/1998-1/2000  
Post-Doc Fellow, Dr. Tora Nakashima, 4/1998-3/2000  
Post-Doc Fellow, Dr. Tarek El-Baradie, 5/2001-4/2003  
Post-Doc Fellow, Dr. Manu Gujrati, 8/2001-6/2004

**Clinical Residents and Fellows**

Fellow, Dr. Russell Beckhardt, 7/1993-6/1994  
Fellow, Dr. Stephen Mobley, 7/1995-4/1996  
Fellow, Dr. Randall Breau, 7/1995-6/1996  
Fellow, Dr. Mitchell Frederick, 4/1996  
Resident, Dr. Michael Sicard, 7/1996-12/1996  
Fellow, Dr. Douglas Frank, 7/1996-6/1997  
Resident, Dr. Andrew McWhorter, 1/1997-6/1997  
Fellow, Dr. Andrew Nemachek, 7/1997-8/1998  
Fellow, Dr. Paul M. Spring, 7/1998-6/1999  
Fellow, Dr. Bryan Potter, 7/2001-6/2003  
Fellow, Dr. Hernan Gonzalez, 7/2001-6/2003  
Fellow, Dr. Kristen Pytynia, 7/2002-6/2004  
Fellow, Dr. Christian Simon, 9/2002-6/2003  
Fellow, Dr. Brian Moore, 7/2003-6/2003  
Fellow, Dr. Seungwon Kim, 7/2003-6/2005  
Fellow, Dr. Thomas Shellenberger, 7/2003-6/2005  
Fellow, Dr. Soon-Hyun Ahn, 7/2006-10/2007  
Fellow, Dr. Mauricio Moreno, MD, 7/2008-7/2009  
Fellow, Dr. Zvonimir Milas, MD, 7/2008-6/2010  
Fellow, Rafael Toro-Serra, MD, 2010-2012

**Other Supervisory Teaching**

Research Mentor, Yaan Kang, PhD, Postdoctoral Researcher, 7/2002-6/2004  
Research Mentee, Abhijit Mazumdar, PhD, 2008-2009  
Visiting Scientist, Junsun Ryu, MD, PhD, 12/2010-12/2011  
Research Mentor, Hu Hei, 9/2014-8/2015  
Muhammet Ayanoglu, 3/2015  
Fan Zhang, MD, PhD, 8/2015-5/2016  
Webin Yu, MD, 9/2015-9/2016  
Kendra Woods, PhD

**Teaching Outside Current Institution**

**Formal Teaching**

**Courses Taught**

Human Gene Therapy, Graduate School of Basic Sciences

**Training Programs**

N/A

**Other Formal Teaching**

N/A

**Supervisory Teaching**

**Committees**

**Advisory Committees**

N/A

**Supervisory Committees**

N/A

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

Research Mentor, M. D. Anderson Cancer Center, Avni Mody, 6/2013-7/2013

**Graduate Students**

N/A

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**CONFERENCES AND SYMPOSIA**

**Organization of Conferences/Symposia (Include chairing session)**

Update on Cutaneous Malignancies of the Head and Neck, Basal and Squamous Cell Carcinoma - Case Management, 14th Annual Cherry Blossom Conference, Washington, DC, Chairman, 3/2001

The University of Texas MD Anderson Cancer Center, Department of Head and Neck Surgery, 2nd Annual Current Concepts in the Management of Thyroid and Parathyroid Neoplasms, Santa Fe, NM, Chair, 2007

The University of Texas MD Anderson Cancer Center, Head and Neck Surgery, 3rd Annual Current Concepts in the Management of Thyroid and Parathyroid Neoplasms, Santa Fe, NM, Chair, 2009

The University of Texas MD Anderson Cancer Center, Head and Neck Surgery, 4th Annual Current Concept in the Management of Thyroid and Parathyroid Neoplasms, Santa Fe, NM, Chair, 10/2011

The University of Texas MD Anderson Cancer Center, Head and Neck Surgery, 5th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms, Houston, TX, Chair, 3/2013

The University of Texas MD Anderson Cancer Center, Head and Neck Surgery, 6th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms, Houston, TX, Chair, 2/2015

The University of Texas MD Anderson Cancer Center, Head and Neck Surgery, 7th Current Concepts in the Management of Thyroid and Parathyroid Neoplasms, Houston, TX, Chair, 2/2017

**Presentations at National or International Conferences**

**Invited**

Developing Gene Transfer in Head and Neck Cancer Plenary Presentation and Head and Neck Cancer, XVI International Cancer Congress, New Delhi, India, 5/1/1994

4th International Conference on Head and Neck Cancer Management of N Positive Neck: Meet the Professor, Toronto, Canada, 7/1/1996

Her-2/neu Regulation of Aggressive Phenotypic Behavior, 4th International Conference, Toronto, Canada, 8/1/1996

Basic and Clinical Research in Head and Neck Cancer, 10th International Symposium of the Foundation for Promotion of Cancer Research, Tokyo, Japan, 4/1/1997

Gene Therapy, Molecular Biology, Oral and Upper Aerodigestive Tract Malignancies,, Institute of Dental Research, Washington, D.C.,, 9/1/1997

Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma, International Symposium on Metastases in Head and Neck Cancer, Kiel, Germany, 1/1/1998

Neoplasms of the Salivary Gland, 20th Annual Sisson International Head and Neck Workshop, Vail, CO, 2/1/1998

New Frontiers in Research and Treatment of Aerodigestive Tract Cancers, 41st Annual Clinical Conference, Houston, TX, 4/1/1998

Simposio Internacional de Oncologia X Aneversario del Grupo Oncopaz, Conferencia de Clausura: Terapia Genica,, Madrid, Spain, 5/1/1998

The Use of Modified Virus to Fight Cancer, Erocancer 98, Paris, France, 6/1/1998

American Academy of Otolaryngology-Head and Neck Surgery, Alternative Oncologic Surgical Approaches Preserving Function, San Antonio, Texas, 9/1/1998

Gene Therapy for Head and Neck Cancer, 2nd International Symposium in Israel on Head and Neck Surgery and Oncology, Israel, 11/1/1998

Is Neck Dissection Necessary after Chemotherapy/Radiotherapy Treatment for Node Positive Squamous Cell Carcinoma of the Pharynx, American Head and Neck Society, Philadelphia, PA, 4/1/1999

Oncologic Organ and Function Sparing Surgical Approaches, 1999 American Academy of Otolaryngology-Head and Neck Surgery Foundation Annual Meeting, New Orleans, LA, 9/1/1999

Developing Novel Therapy for Head and Neck Cancer, First International Chicago Symposium on Malignancies of the Chest and Head & Neck,, Chicago, IL, 10/1/1999

Society of Surgical Oncology 53rd Annual Symposium, Lymphatic Mapping in Head and Neck Melanoma, New Orleans, LA, 3/1/2000

Developing Novel Therapy for Head and Neck Cancer, 5th International Conference on Head and Neck Cancer, San Francisco, CA, 7/1/2000

Oncologic Organ and Function Sparing Surgical Approaches and Medullary Thyroid Carcinoma: Current Management, American Academy of Otolaryngology – Head and Neck Surgery Foundation, Washington, D.C, 9/1/2000

Presidential Address – Developing Novel Approaches for Head and Neck Cancer, 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Boston, MA, 10/1/2000

Developing Adenovirus p53 Gene Transfer in Head and Neck Squamous Carcinomas – A Decade of Progress, 2001 International Symposium on Cancer Gene Therapy, Chiba, Japan, 9/1/2001

Current Concepts in Parotid and Parapharyngeal Tumors,, 24th Annual Session International Head and Neck Workshop, Vail, CO, 2/1/2002

Local Gene Therapy, 7th Annual Oncology Conference Targeted Diagnostics & Therapy and 2nd Annual Scientific Session Cancer-Specific Radiopharmaceuticals, St. Louis, MO, 4/1/2002

Medullary Thyroid Carcinoma: Current Management, American Academy of Otolaryngology-Head & Neck Surgery 2002 Annual Meeting, San Diego, CA, 9/1/2002

Treating Neck Spread of Thyroid Cancer, 5th International Thyroid Cancer Survivors Conference, Los Angeles, CA, 10/1/2002

Current Concepts in Adjuvant and Viral Therapy, 71st Annual Scientific Meeting of ASPS/PSEF/ASMS, San Antonio, TX, 11/1/2002

Dilemmas in Diagnosis and Treatment, 25th Annual Sisson International Head and Neck Workshop on Oral Cavity: From Aphthous Ulcers to SCCa, Vail, CO, 2/1/2003

American Head and Neck Society Annual Meeting, Nashville, TN, 5/1/2003

American Association for Cancer Research 94th Annual Meeting 2003, Washington, DC, 7/1/2003

American Academy of Otolaryngology-Head and Neck Surgery Foundation 2003 Annual Meeting, Orlando, FL, 9/1/2003

Parathyroids, Neck Dissection, Multiple Surgeries, Neck Spread, 6th International Thyroid Cancer Survivors' Conference, Houston, TX, 10/1/2003

American Association for Cancer Research 95th Annual Meeting, Orlando, Florida, 3/1/2004

Management of Differentiated Thyroid Cancer– Practice Study, University of Pisa National Specialty Hospital, Pisa, 7/1/2004

Piercy Presentation – Translating Bench to Bedside, 6th International Conference on Head and Neck Cancer, Washington, DC, 8/1/2004

Management of Differentiated Thyroid Cancer, American Academy of Otolaryngology-Head and Neck Surgery Foundation 2004, New York, NY, 9/1/2004

Molecular Medicine Symposium, Houston, TX, 2/1/2005

ATA Thyroid Cancer Symposium, Baltimore, MD, 4/1/2005

10th International Congress on Oral Cancer, Island of Crete, Greece, 4/1/2005

American Head & Neck Society Annual Meeting, Boca Raton, FL, 5/1/2005

13th SPORE Investigators' Workshop, Washington, DC, 7/1/2005

Executive Council Meeting, American Head and Neck Society, Chicago, IL, 8/2006

Nuances in the Management of patients with recurrent papillary thyroid carcinoma, 58th Annual Meeting of the Japan Broncho-Esophageal Society, Sapporo, Japan, 10/2006

Endocrine Surgery: How do we avoid fragmentation?, American Head and Neck Surgery, Rosemont, IL, 3/1/2007

Attendee, American Association for Cancer Research, Los Angeles, CA, 4/2007

Minimally Invasive Thyroid & Parathyroid Surgery, 18th Annual Controversies in the Management of Thyroid and Parathyroid Diseases, Institute for Head and Neck and Thyroid Center, Tarrytown, NY, 4/2008

Metastatic/Recurrent Aggressive Thyroid Cancer, 7th Intl Conference on Head and Neck Cancer, AHNS, San Francisco, CA, 7/18/2008

Head and Neck Surgeon's Perspective; What the Surgeon Needs to Know from the Radiologist., Comprehensive Course in Oncologic Imaging, The University of Texas MD Anderson Cancer Center, Philadelphia, PA, 10/15/2008

Contemporary Management of Thyroid Cancer; Multidisciplinary Evaluation & Treatment of Advanced Thyroid Cancer, NWAO 2009 Winter Conference, Northwest Academy of Otolaryngology, Seattle, WA, 1/10/2009

Difficult thyroid cases, American Association of Clinical Endocrinologists, Houston, TX, 5/14/2009

Panel Presentation: Neck Metastasis Detection and Treatment, World Congress on Thyroid Cancer, Toronto, Canada, 8/8/2009

Management of Differentiated Thyroid Cancer, AAO-HNS Annual Meeting, San Diego, CA, 10/4/2009

Clayman. Challenging Head and Neck Case Presentations, Cancer Symposium, University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering, New York, NY, 8/17/2010

Clayman GL. Miniseminar: New Medullary thyroid cancer guidelines: What we need to know., Annual Meeting AAO-HNS, AAO-HNS, Boston, MA, 9/28/2010

Surgical Therapy for Differentiated Thyroid Malignancies, American Society of Head and Neck Radiology, Houston, TX, 10/9/2010

Contemporary Surgical Treatment of differentiated Thyroid Cancer and Recurrent Thyroid Cancer, 13th International Thyroid Cancer Survivors Conference, ThyCa: Thyroid Cancer Survivors Assoc., Dallas, TX, 10/15/2010

Surgery for persistent & recurrent thyroid cancer, UCSF Head & Neck Endocrine Surgery Course, University of California San Francisco, San Francisco, CA, 10/22/2010

1) Remote Access Robotic Thyroid Surgery; 2) Parathyroid auto transplantation: How I do it?, 20th Annual Hands on Course in Controversies in the Management of Thyroid & Parathyroid Diseases, THANC Foundation, White Plains, NY, 3/23/2011

Surgical Management of Recurrent or Persistent Differentiated Thyroid Cancer, 2nd Annual Pacific Northwest Head, Neck & Thyroid Cancer Symposium, SCCA Network & Physicians Outreach, Seattle, WA, 4/6/2012

1) Surgical Management of Minimally Invasive to Aggressive Thyroid Cancers; 2) Surgical Management of Recurrent or Persistent Thyroid Cancer, University of Arkansas for Medical Sciences Department of Otolaryngology - Head and Neck Surgery, Little Rock, AR, 6/23/2012

1) Moderator-Preferred Papers: "Best Of" Clinical I; 2) Advanced Regional Disease: Establishing the Limits of Surgical Resection, American Head and Neck Society, Toronto, Canada, 7/22/2012

**G L Clayman.** Recognition and Management of Complication, American College of Surgeons, Chicago, IL, 10/2/2012

The Surgeon's Role in Multidisciplinary Care, International Federation of Oto-Rhino-Laryngological Societies (IFOS), Seoul, Korea, Republic of, 6/3/2013

Moderator. Extent of Surgery for Well Differentiated Thyroid Cancer, International Federation of Oto-Rhino-Laryngological Societies (IFOS), Seoul, Korea, Republic of, 6/4/2013

Panelist. Malignant Salivary Gland Neoplasms- Surgical Management, International Federation of Oto-Rhino-Laryngological Societies (IFOS), Seoul, Seoul, Korea, Republic of, 6/4/2013

Video Session How I Do It, 2nd World Congress on Thyroid Cancer, West Toronto, Canada, 7/12/2013

Gary Clayman, DMD, MD, FACS. Evaluation and Surgical Management of Recurrent/Persistent Nodal DTC and MTC: and Advancing, Structurally Invasive Thyroid Cancer, AACE Annual Thyroid Cancer Program, Phoenix, AZ, 1/17/2014

Panel Member- Case Management Discussions, AACE Annual Thyroid Cancer Program, Phoenix, AZ, 1/18/2014

Panel Member-Case Management Discussions: Current Controversies in the Surgical Management of Thyroid Cancer, AACE Annual Thyroid Cancer Program, Phoenix, AZ, 1/18/2014

Update of NCI Clinical Trials Meeting in Differentiated Thyroid Cancer, NRG (RTOG) Head & Neck Surgical Subcommittee, San Diego, CA, 2/8/2014

Nuances in well-differentiated thyroid carcinoma panel, IFHOS/AHNS, New York, NY, 7/27/2014

Management of Persistent/Recurrent Differentiated Thyroid Cancer: When to Treat, When to Watch?, American Thyroid Association, Coronado, CA, 10/2014

Thyroid Cancer Panel, Turkish Association of Endocrine Surgeons, Istanbul, Turkey, 10/2014

Revision surgical strategies for PTC nodes, Harvard Thyroid Course, Harvard Medical School, Boston, MA, 12/2014

Thyroid Cancer, National Conference on Head and Neck Cancer Processing of Diagnosis and Treatment, Qilu Hospital of Shandong University, Qingdao, China, 8/28/2015

Initial Surgery- Extent/Complications/Communication, Advances in Medical and Surgical Management of Thyroid Cancer, American Association of Clinical Endocrinologists, Tempe, AZ, 1/2016

Surgical Management of Differentiated Thyroid Cancer, AACE Florida Chapter Annual Meeting, American Academy of Clinical Endocrinologists, Orlando, FL, 8/2016

Surgery for Recurring and Locally Advanced Disease, Advances in Medical and Surgical Management of Thyroid Cancer, American Association of Clinical Endocrinologists, Tampa, FL, 1/2017

#### **Other, Including Scientific Exhibitions**

Review p50s, Review Panel, NCI, Bethesda, MD, 9/2005

Management of Head & Neck Cancer, Mgmt of Neck Masses, Surgical Mgmt of Oral Cavity Malignancy, Tumors of the Larynx, Non-Melanoma Skin, Mgmt of Thyroid Nodule and Parathyroid Neoplasms., Cruising with the Master Head & Neck: Radiology and Oncology, England, United Kingdom, 8/2008

Clayman G. Scientific Session "Src inhibitors induce apoptosis in papillary thyroid carcinoma cells," AHNS 2009 Annual Meeting, Phoenix, AZ, 5/31/2009

Surgery for Recurrent Thyroid Cancer, UCSF Head and Neck Cancer and Endocrine Surgery Update, The University of California- San Francisco, San Francisco, CA, 11/2014

Surgery for Recurrence and Locally Advanced Disease, Advances in Medical and Surgical Management of Thyroid Cancer, American Association of Clinical Endocrinologists, Tempe, AZ, 1/2016

Thyroid Cancer Case Discussion/Management, Advances in Medical and Surgical Management of Thyroid Cancer, American Association of Clinical Endocrinologists, Tempe, AZ, 1/2016

Changing Landscape in Management of Thyroid Cancers, 9th International Conference on Head & Neck Cancer, American Head and Neck Society, Seattle, WA, 7/2016

#### **Seminar Invitations from Other Institutions**

Seminar: Molecular Biology in Head and Neck Cancer, University of Arkansas, Little Rock, AR, 12/1/1992

Seminar: Adeno p53 Gene Transfer in a Phase I/II Trial of Patients with Advanced Recurrent Head and Neck Squamous Carcinoma, National Cancer Institute, Washington, D.C., 10/1/1996

Nuances in the Management of Differentiated Thyroid Cancer Seminar: Aggressive Non-Melanoma Skin Cancer, Minnesota Academy of Otolaryngology, Minneapolis, MN, 11/1/1996

Gene Transfer Strategies in Head and Neck Cancer, NCI Strategy Meeting, Bethesda, MD, 12/1/1997

Seminar: Head and Neck Surgical Oncology in the Next Century, University of Iowa, Department of Otolaryngology, Iowa City, IA, 4/1/2000

Seminar: Head and Neck Surgical Oncology for the Next Millennium – Developing Targeted Therapeutic Approaches,, National Institute of Dental and Cancer Research, Bethesda, MD, 12/1/2000

Head and Neck Cancer Etiology and Biology: Research Directions and Therapeutic Opportunities, Think Thank Workshop: National Institutes of Health, Georgetown Washington, D.C., 5/1/2004

Review SPORE Applications, NCI SPORE, Washington, DC, 2/12/2009

1) Management of Aggressive Thyroid Cancer: How aggressive do we need to be? 2) Central lymph node dissection: Why, when and how?, 4th Annual Symposium: Contemporary Management of Thyroid and Parathyroid Diseases, Tulane University Health Sciences Center, New Orleans, LA, 6/9/2012

Reoperation for recurrent thyroid cancer disease, 4th Annual Symposium: Contemporary Management of Thyroid and Parathyroid Diseases, Tulane University Health and Sciences Center, New Orleans, LA, 6/10/2012

Management of Aggressive Thyroid Cancer, Tulane University School of Medicine, Medicine and Surgery and Tulane University Health Sciences Center, Center of Continuing Education, New Orleans, LA, 2/16/2013

Modified Neck Dissection, Tulane University of Medicine, Medicine and Surgery and Tulane University Health Sciences Center, Center for Continuing Education, New Orleans, LA, 2/16/2013

Tips to Avoid Complications During Neck Dissections, Tulane University School of Medicine, New Orleans, LA, 2/17/2013

#### **Lectureships and Visiting Professorships**

Grand Rounds, Mount Sinai Hospital Grand Rounds, Novel Diagnosis and Therapy in Head and Neck Cancer, Grand Rounds, Mount Sinai Hospital Grand Rounds, Detroit, MI, 3/1/1996

Grand Rounds, University of Kentucky Chandler Medical Center, New Trends in the Management of Head and Neck Cancer,, Lexington, KY, 9/1/1996

Preliminary Results of a Phase I clinical study of Ad-p53 in Head and Neck Squamous Cell Carcinoma, -, Chantilly, VA, 11/1/1996

P53 Restorative Therapy in Head and Neck Malignancy - Translating Bench to Bedside, Society of Surgical Oncology, Inc., Chicago, IL, 3/1/1997

Managing Innovation, Clinical Experience in Head and Neck Cancer, RPR-Gencell Symposium on Gene Therapy, -, Boca Raton, FL, 6/1/1997

Memorial Sloan Cancer Center, Wild-type p53 Gene Transfer via an Adenoviral Vector in Patients with Recurrent Head and Neck Cancer, New York, NY, 6/1/1997

The New York Hospital-Cornell University Medical College Stubenbord Lecturer, Historical Perspectives and New Strategies in the Management of Head and Neck Melanoma and Adenovirus Mediated p53 Gene Transfer for Patients with Advanced Recurrent Head and Neck, New York, NY, 6/1/1997

13th Annual Max Som Lecture, Adenovirus Mediated p53 Gene Transfer in Patients with Advanced Squamous Carcinoma of the Head and Neck, Montefiore Medical Center, Bronx, NY, 4/1/1998

Adenovirus Medicate p53 and Oncolytic Viruses, 5th Research Workshop, McLean, VA, 8/1/1998

Cancer of the Oral Cavity and Oropharynx, St. Francis Cabrini Hospital, Alexandria, LA, 11/1/1999

Technology Futures Panel on Oncology, -, St. Petersburg, FL, 2/1/2000



Head and Neck Surgical Oncology-The next Millennium, Henry Ford Hospital Resident Research Day,, Detroit, MI, 6/1/2000

Gene Therapy for Head and Neck Cancer, Norton Healthcare Oncology Symposium, -, Louisville, KY, 9/1/2000

Milestones in Oncology: A New Treatment for Head and Neck Cancer, An Advisory Board for Matrix Pharmaceuticals, Inc., -, Scottsdale, AZ, 12/1/2000

Presidential Invitation, Kennebunkport, ME, 7/1/2001

Developing Novel Therapies in Head and Neck Cancer, 100th Anniversary of the University of Minnesota D, Minneapolis, MN, 6/1/2002

Grand Rounds, Head and Neck Cancer Surgery – Thinking Outside the Box, UT San Antonio, San Antonio, 4/1/2003

American Society of Head & Neck Radiology, Biology of Head and Neck Cancer, Rancho Mirage, CA, 10/1/2003

Wisconsin Society of Otolaryngology Head and Neck Surgery; Management of Differentiated Thyroid Malignancies; Head and Neck Cancer-Where Are We Going?, Lake Geneva, WI, 10/1/2003

Molecular Anatomy of Head and Neck Cancer: A Genomic/Proteomic Approach, National Institute of Dental and Craniofacial Rese, Bethesda, MD, 11/1/2003

Sacramento Society of Otolaryngology, Thyroid Cancer, Sacramento, CA, 11/1/2003

Management of Differentiated Thyroid Cancer; Developing Novel Therapy for Head and Neck Cancer, University of North Carolina, Chapel Hill, NC, 12/1/2003

LSU-HSC Spring Cancer Seminar Series, Head and Neck- Where Are We Going?, Shreveport, LA, 2/1/2004

The Second Annual Opinion Leader Consortium on Novel and Targeted Therapies for Head and Neck Cancer; p53 Gene Transfer in Reversing the Clinical and Histologic Appearance of Oropharyngeal Premalignancies, Montego Bay, Jamaica, 2/1/2004

Mayo Clinic Foundation, Department of Otorhinolaryngology, Developing Targeted Therapy for Head and Neck, Rochester, MN, 8/1/2004

Translational Research in Head and Neck Cancer-A Call to Arms: Understand the Definition of "Translational Research"; Describe Current Paradigms in Translational Research in Head and Neck Cancer; Understand the Current Obstacles and Areas to Enhance Resea, University of Chicago, Chicago, IL, 9/1/2004

Grand Rounds, Duke University Medical Center, Nuances in the Management of Differentiated Thyroid Cancer, Durham, NC, 10/1/2004

Grand Rounds, University of Pittsburgh Medical Center, Nuances in the Management of Aggressive and Recurrent Thyroid Cancer, Pittsburgh, PA, 5/1/2005

Management of Medullary Thyroid Carcinoma/Surgical Treatment of Cancer of the Oral Cavity, Memorial-Sloan Kettering Hospital, New York, NY, 11/2005

Contemporary Management of Parathyroid Neoplasia / Surgical Management of Recurrent Thyroid Carcinoma / Surgery for Thyroid Malignancy from Video-Assisted Thyroidectomy to Management of Aggressive Thyroid Cancers, 10th Annual Summer Update in Otolaryngology, The University of Wisconsin School of Medicine and Public Health, Beaver Creek, CO, 7/2006

Advisory Board Meeting, Head & Neck, Sanofi-Aventis, Chicago, IL, 10/2006

Technological advances in Minimally Invasive Head & Neck Surgery, Training Course, Ethicon Endo-Surgery, Inc., Oklahoma, KS, 10/2006

Management of Cutaneous SCC: The US Experience / Papillary Thyroid Carcinoma from Video-Assisted Surgery to Aggressive Invasive Thyroid Cancer Resections / Management Dilemmas of

Incurable Recurrent Disease, 9th Annual Scientific Meeting, ANZHNS, Brisbane, Australia, 7/2007

Management of Head & Neck Masses; Management of Aggressive Cutaneous Squamous Cell Carcinoma, American College of Mohs Surgery, Vancouver, Canada, 5/1/2008

Minimally Invasive Thyroidectomy; Management of the neck in differentiated Thyroid cancer; Surgical Management of Recurrent Thyroid Cancer, 22nd Annual Madigan Head & Neck Conference, Department of Army, Western Regional Medical Command and Madigan Army Medical Center, Tacoma, WA, 7/24/2008

Robotic Surgery on the head and Neck: Science Fiction?; Management of the advanced non-melanoma skin cancers of the head and neck; Targeted therapy of head and neck cancer., Instituto de Ensino e Pesquisa, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 8/2008

Management of differentiated thyroid cancer: from minimally invasive to aggressive thyroid malignancies, Grand Rounds, Kettering Hospital, Boonshoft School of Medicine, Wright State University, Department of Surgery, Dayton, OH, 4/14/2009

Advancement in Head and Neck Minimally Invasive Procedures, Ethicon Endo-Surgery, Phoenix, AZ, 6/9/2009

Management of Recurrent and Aggressive Thyroid Cancer, Herbert Birkett Memorial Lecture, Otolaryngological Section medico Chirurgical Society, Otolaryngology, Montreal, Canada, 11/12/2009

Reoperation for Recurrent Thyroid Cancer Disease, 3rd Symposium on Thyroid and Parathyroid Diseases, Tulane University, New Orleans, LA, 3/19/2011

Contemporary Management of Locally Aggressive Thyroid Cancer, UPMC 3rd Annual Advanced Topics in Thyroid and Parathyroid Surgery, University of Pittsburgh School of Medicine, Otolaryngology, Pittsburgh, PA, 5/13/2011

Revision nodal surgery for PTC: MDA Experience, Surgery of the Thyroid and Parathyroid Glands, Harvard Medical School Massachusetts Eye & Ear Infirmary, Otolaryngology, Boston, MA, 11/11/2011

Surgical Management of Persistent/Recurrent Differentiated Thyroid Cancer, Seoul National University Hospital, Seoul, Korea, Korea, Republic of, 6/13/2014

Approached to the Management of the Early Stage Papillary Thyroid Cancer and Persistent-Recurrent Disease, National Cancer Center, Seoul Korea, Korea, Korea, Republic of, 6/16/2014

Grand Rounds, Ohio State University, Contemporary Surgical Management of Recurrent or Persistent Differentiated Thyroid Cancer and Developing a Faculty Mentoring Program in the Cancer Center, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 2/5/2016

Contemporary Surgical Management of Differentiated Thyroid Cancer, Austin Society of Otolaryngology, Austin, TX, 3/2016

#### **Other Presentations at State and Local Conferences**

Developing Gene Therapy for Head and Neck Cancer, UT MD Anderson Cancer Center Grand Rounds, Houston, TX, 8/1/1994

Dallas Academy of Otolaryngology, Past Perspectives and New Strategies in the Management of Head and Neck Melanoma, Dallas, TX, 3/1/1997

Developing Novel Therapies in Head and Neck Cancer, Grand Rounds, The University of Texas Medical Bran, Galveston, TX, 5/1/2002

UT MD Anderson Cancer Center Oncologic Dentistry & Maxillofacial Prosthetics Symposium, Houston, TX, 3/1/2003

Progress in Interdisciplinary Head and Neck Cancer Research, UT MD Anderson Cancer Center Grand Rounds, Houston, TX, 5/1/2003

3rd Inter-SPORE, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1/2005

DOS-Surgical Education Session, The University of Texas M.D. Anderson Cancer Center, 2/1/2005

Molecular, Medicine Symposium, UT M.D. Anderson Cancer Center, Houston, TX, 2/2005

Headpin: An Endogenous & Exogenous Suppressor of Angiogenesis in HNSCC, 13th Inter-SPORE Investigators' Workshop, UT M.D. Anderson Cancer Center, Washington, DC, 7/2005

Surgical Management of Differentiated Thyroid from Minimally Invasive to Aggressive Therapies, Current Concepts in the Management of Thyroid & Parathyroid Neoplasms, UT M.D. Anderson Cancer Center, Head & Neck Surgery, Houston, TX, 10/2005

Reoperation of Central & Lateral Neck in DTC, American Association of Clinical Endocrinologists, Dallas, TX, 11/2005

Surgery for Differentiated Thyroid Cancer, Core Curriculum, UT M.D. Anderson Cancer Center, Head & Neck Surgery, Houston, TX, 2006

Surgical Management of Differentiated Thyroid Cancer, UT M.D. Anderson Cancer Center, Pathology & Laboratory Medicine Grand Rounds, Houston, TX, 1/2006

Thoughts on Thyroid Cancer, Management of Medullary Thyroid Carcinoma, Teaching Faculty, Audio-Digest Foundation, n/a, 2006

External Scientific Advisory Board, SPORE in Head & Neck Cancer, UT M.D. Anderson Cancer Center, 2/2006

Meeting, 4th InterSPORE Winter Meeting, UT M.D. Anderson Cancer Center, Houston, TX, 2/2006

Differentiated Thyroid Carcinoma / Role of the Research Laboratory in Thyroid Carcinoma, Clinical Preceptorship on Multidisciplinary Aspects of Thyroid Cancer Management, UT M.D. Anderson Cancer Center, Houston, TX, 3/2006

Thyroid, Parathyroid, Minimally Invasive Approach, Training Course, Ethicon Endo-Surgery, Inc., Dallas, TX, 5/2006

What's New in Thyroid Surgery, Ethicon Endo-Surgery, Inc., Baylor College of Medicine, Houston, TX, 9/2006

Current Concepts, Current Concepts in Head and Neck Surgery, UT M.D. Anderson Cancer Center / Memorial Sloan-Kettering Cancer Center, Houston, TX, 11/2006

Tracheoesophageal Surgery and Reconstruction Surgery for Locally Advanced Thyroid Cancer, Grand Rounds, UT M.D. Anderson Cancer Center, Houston, TX, 12/2006

Surgery for Advanced Thyroid Cancer, Tracheoesophageal Surgery and Reconstruction, UT M.D. Anderson Cancer Center, Houston, TX, 12/8/2006

Differentiated Thyroid Carcinoma, Clinical Preceptorship on Multidisciplinary Aspects, UT M.D. Anderson Cancer Center, Endocrine Neoplasia and Hormonal Disorders, Houston, TX, 3/22/2007

Thyroid Surgery, Where are we going?, Grand Rounds, DoS Grand Rounds, Division of Surgery, Head and Neck Surgery, Houston, TX, 6/27/2007

Thyroid, Parathyroid, Minimally Invasive Approach, Training Course, Ethicon Endo-Surgery, TX, 2008

Video assisted Thyroidectomy; Management of Recurrent Disease, Current Concepts in Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Head and Neck, Houston, TX, 11/15/2008

Translational Research in Thyroid Cancer from Bench to Bedside, MD Anderson Cancer Center Orlando Research Symposium, University of Texas M.D. Anderson Cancer Center, Research, Orlando, FL, 10/28/2009

Management of Recurrent Disease, University of Texas MD Anderson Cancer Center, Houston, TX, 11/21/2010

Endocrine I - Management of Recurrent Disease, Current Concepts in Head and Neck Surgery, MD Anderson Cancer Center, Head and Neck Surgery, Houston, TX, 11/2012

**PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

**Professional Society Activities, with Offices Held**

**National and International**

American Academy of Otolaryngology-Head and Neck Surgery  
Member, 1995-present

American College of Surgeons  
Member, 1995-present

American Society of Clinical Oncology  
Member, 1995-present

American Head and Neck Society  
Member, 2003-present

American Thyroid Association  
Member, 2005-present

Endocrine Surgery - American Head and Neck Society  
Committee Chair, 2007-present

American Association of Clinical Endocrinologists  
Member, 4/2013-present

Houston Society of Otolaryngology/Head & Neck Surgeons

American Academy of Facial Plastic and Reconstructive Surgery

American Association for Cancer Research

American Dental Association

American Medical Association

American Radium Society

American Skull Base Society

Harris County Medical Society

Society of University Otolaryngologists

Texas Medical Association

**Local/State**

N/A

**UNIQUE ACTIVITIES**

1. Panel member of OncLive Peer Exchange in Chicago, IL on June 3, 2014

2. Panel Member at Lenvima National Broadcast in New York, NY on May 20th, 2015